Curriculum vitae | Codrina Irena Mihaela ANCUTA

1 | P a g e

CURRICULUM VITAE

Nume si prenume: ANCUTA Codrina Irena Mihaela

Nume anterior casatoriei: CHIRIEAC

Locul si data nasterii:

Adresa:;

Date contact:

Stare civila:

Pozitie profesionala si academica actuala

medic primar specialitatea Reumatologie; medic primar specialitatea Recuperare Medicala, Medicina Fizica si Balneologie; doctor in medicina; sef lucrari univ Disciplina Reumatologie-Balneofizioterapie, Departamentul Medicale II,

Universitatea de Medicina si Farmacie “Gr.T.Popa” Iasi; coordonator Centru EUSTAR 162

Loc de munca actual

1Universitatea de Medicina si Farmacie “Gr.T.Popa” Iasi, Facultatea de Medicina, Disciplina Reumatologie – Balneofizioterapie (din 1995);

2Spitalul Clinic de Recuperare Iasi, Clinica Reumatologie II, sef clinica (din 2013);

Studii

1984-1988: Liceul “Emil Racovita”, profil matematica-fizica; absolventa a promotiei iunie 1998, diploma de bacalaureat seria E Nr.39358 (media generala examen bacaureat 9.62);

1988-1994: Universitatea de Medicina si Farmacie “Gr.T.Popa” Iasi, Facultatea de Medicina; absolventa a promotiei 1994, diploma de medic - doctor: diploma M nr. 041128; media generala de promovare a anilor de studiu 9.98; media generala de licenta 9.99 (sesiunea sept 1994);

Titluri stiintifice

Doctor in Medicina (seria E nr. 0002743) (ordin MEC nr 3824/03.05.2006); titlul tezei: Miopatia inflamatorie in poliartrita reumatoida/ Inflammatory myopathy in

rheumatoid arthritis conducator de doctorat: prof univ dr George Ioan Pandele; 1998-2005: doctorand, data sustinerii tezei de doctorat: 15 iulie 2005

Experienta in specialitate si locuri de munca relevante

01.02.1995-02.10.1995: medic rezident specialitatea Pneumoftiziologie prin concurs (OMS 2213/1994), Spitalul Clinic de Pneumoftiziologie Iasi

Reumatologie

1996-1999: medic rezident in specialitatea Reumatologie (OMS nr. 715/27.03.1996), Clinica de Reumatologie, Spitalul Clinic de Recuperare Iasi

1999 -2003: medic specialist Reumatologie (OMS nr. 900/ 20.10.1999; medie 9.17), Clinica de Reumatologie, Spitalul Clinic de Recuperare Iasi

din 2003: medic primar specialitatea Reumatologie (OMS nr. 846/ 12.09.2003; medie 9.66), Clinica de Reumatologie, Spitalul Clinic de Recuperare Iasi

Recuperare Medicala, Medicina Fizica si Balneologie

Curriculum vitae | Codrina Irena Mihaela ANCUTA

2 | P a g e

1999-2002: medic rezident in specialitatea Recuperare, Medicina Fizica si Balneologie, Clinica de Reumatologie, Spitalul Clinic de Recuperare Iasi

2002-2008: medic specialist Recuperare, Medicina Fizica si Balneologie (OMS nr 256/11.04.2002; media 9.33), Clinica de Reumatologie, Spitalul Clinic de Recuperare Iasi

din 2008: medic primar specialitatea Recuperare, Medicina Fizica si Balneologie (OMS 1971/03.12.2008; media 10.00), Clinica de Reumatologie, Spitalul Clinic de Recuperare Iasi

Experienta didactica si locuri de munca relevante

2.10.1995-01.03.1999: preparator universitar prin concurs, Disciplina Reumatologie-Balneofizioterapie, Universitatea de Medicina si Farmacie “Gr.T.Popa” Iasi

05.03.1999-01.03.2004: asistent universitar prin concurs (decizia 2825/05.03.1999), Disciplina Reumatologie-Balneofizioterapie, Universitatea de Medicina si Farmacie “Gr.T.Popa” Iasi

din 01.03.2004 - in prezent: Sef lucrari univ prin concurs, Disciplina Reumatologie-Balneofizioterapie, Universitatea de Medicina si Farmacie “Gr.T.Popa” Iasi

Cursuri de formare medicala (nationale, internationale) si specializari

Nationale

Curs Management Spitalicesc, Scoala Nationala de Sanatate Publica si Management Sanitar, 14.02-28.03.2008, Bucuresti, Romania (seria A, nr. 00331);

Supraspecializare in Boli osoase endocrino-metabolice (certificate de absolvire curs seria D, Nr 0011216) martie-nov 2003, Iasi, Romania; Certificat de supraspecializare in Patologie osoasa endocrino-metabolica seria C Nr. 013718

Curs Laser-terapie, 01.03-31.05.2001, Iasi, Romania, certificate de absolvire curs seria A, nr 0009588

Curs intensiv Metode moderne de tratament al copilului spastic, 21-23.09.2000, Bucureti, Romania

Curs postuniversitar Algeziologie (durerea si tratamentul ei), 23.04-21.05.1999, UMF “Gr,T.Popa” Iasi (certificat de absolvire seria B, nr 0003658)

Internationale

Curs imagistica: Imagistica in bolile reumatice, 01 oct 2014, Bucuresti, Romania 3rd Annual Meeting of the Lupus Academy, 7-9 March 2014 Berlin, Germany Pain Refresher Course, 2nd May 2013, Singapore 2nd SE Europe Course Systemic Lupus Erythematosus, 25.09.2013, Bucuresti, Romania APLAR Musculoskeletal Ultrasound Course in Rheumatology, The 15th Congress pf the Asia

Pacific League of Associatios for Rheumatology, 10-14 Sept 2012, Dead Sea, Amman, Jordan Al doilea Curs International de Ecografie Musculoscheletala sub patronaj stiintific EULAR, 8-10

martie 2012 Bucuresti, Romania Workshop: Methodentransfer und neue knozepte rheumatologie, 2-4 Jun 2011, Chisinau, Moldova. ISCD Clinician Bone Densitometry Course, 25-26 feb 2011, Bucharest, Romania. ISCD and IOF FRAX Initiative: Interpretation and Use of FRAX in Clinical Practice, 11-13 nov 2010,

Bucharest, Romania. Curs Internaţional de Osteoporoză cu Certificare în Osteodensitometrie, IOF-OsArt, 27-28 mai

2009, Sinaia, Romania. 6th RCRD International Workshop: Up-to-date in Rheumatology, 27-29 apr 2009, Bucharest,

Romania The 1st Quantitative Ultrasound Densitometry Course, 3-4 july 2008, Bucharest & Iasi Curs EUSTAR: Scleroderma Skin Scoring Course, 11 jul 2008, Cluj-Napoca, Romania Academy of Rheumatology, 18-20 dec 2008, Cairo, Egipt

Curriculum vitae | Codrina Irena Mihaela ANCUTA

3 | P a g e

Program educational de armonizare a managementului PR precoce in concordanta cu recomandarile EULAR- Eupera, Sanofi Aventis (Universitatea Paris VII Franta; platforma electronica www.eupera.org)

Workshop New evidence-based pain control: oxycodone in severe somatic, neuropatic and visceral pain, 23-27 March 2007, Paris, France

4th RCRD (Research Centre on the pathology and treatment of Rheumatic Disorder) International Workshop: Outcomes in Rheumatology, 6-8 dec 2007, Bucharest, Romania (European Commission FP6)

Musculoskeletal ultrasound course, 19-21 Jan 2007, Bucharest, Romania Curs International de Osteoporoza cu Certificare in Osteodensitometrie, 11-14 apr 2007, Cluj-

Napoca, Romania 14th EULAR Intermediate Sonography Course, 10-13 June 2007, Sitges, Barcelona, Spania (sub

patronaj stiintific EULAR) (bursa studiu EULAR); 1st RCRD International Workshop: Advanced Techniques in Bone Research, 28-30 sep 2006

Bucuresti, Romania ISCD Bone densitometry Course, 29-30 sept 2006, Bucuresti, Romania International Musculo-skeletal Sonography Course (EULAR, OSART), 13-16 apr 2005, Cluj-Napoca,

Romania Advancing arthritis therapy: addressing patient needs, 4 Feb 2006, Seville Spain 9th EULAR Sonography Course (from introductory to advanced practical course on musculoskeletal

sonograhy), 9-12 Dec 2004, Paris, France (sub patronaj EULAR) (bursa de studiu EULAR); 1st European Course–Capillaroscopy and Rheumatic Diseases, 10-12 Sep 2004, Genova, Italy (bursa

EULAR); John Humphrey International Course of Immunology on self-tolerance and self-recognition, 15-19

May 2000, Sinaia, Romania; (sub patronaj European Federation of Immunological Societies, RSI, Romanian Society for Immunology – Iasi Branch)

6th EULAR Postgraduate Course in Rheumatology, 18-27 June 2000, Nice, Franta (sub patronaj EULAR) (bursa de studiu EULAR);

30 aug-03 sep 1992, John Humphrey Course on Tumor Immunology, Iasi, Romania

Cursuri Good Clinical Practice (GCP)

CME Program SCEPTER, Introduction to the Clinical Drug Development Process: ICH Good Clinical Practice for Clinical Trial Sites, web-training, 04 Jan 2012

Quintiles Global Learning & Development, Introduction to the Clinical Drug Development Process: ICH Good Clinical Practice for Clinical Trial Sites, web-training, 03 Jan 2012

Pfizer GCP for Investigational Site Staff, Pfizer Partner Learning Solution, web-training, 11 feb 2011

FLEX-LA294 Investigator Meeting, 28029 apr 2011, Barcelona, Spain

Membru al asociaţiilor si organizatiilor profesionale (nationale, europene)

Internationale: EUSTAR (EULAR Scleroderma Trials and Research); IASP (International Association for the Study of Pain) si SIG musculoskeletal pain (subgroup durere musculo-scheletala); ECTS (European Calcified Tissue Society); EMEUNET; Autoimmunity network

Nationale: Societatea Romana de Reumatologie; Asociatia de Recuperare Nord Est (membru fondator; 2009); RHEUMA-NORD EST – asociatie profesionala reumatologie (presedinte si membru fondator; 2014); Colegiul Medicilor din Romania (CMI 2409/05.10.2011)

Limbi de circulatie internationala cunoscute

Engleza – nivel B2 (atestat EuroEd, certificat absolvire nr 019/05 dec 2010; certificat de absolvire Funny English center Curs avizat de Ministerul Invatamintului nr 25410/18.03.1997 si Autorizat Consiliul National de Formare a Adultilor decizia 22/240 din 11.04.2008);

Curriculum vitae | Codrina Irena Mihaela ANCUTA

4 | P a g e

Franceza (nivel B2; atestat DALF- Diplome Approfondi de la Langie Francais 12/04/1995 – no 04000100097)

Membru în colectivele de redacție ale revistelor de specialitate, in consiliul peer-review

Membru in Colegiul de Redactie al Revistei Romane de Reumatologie

Invited peer-reviewer pentru reviste cotate ISI (Clinical Rheumatology, European Journal of Physical and Rehabilitation Medicine);

Membru consiliul peer-review al Revistei Romane de Reumatologie (Editura Medicala Amaltea, Bucuresti; ISSN: 1843-0791; eISSN: 2069-6086, Cod CNCSIS: 378, B+)

Invited peer-reviewer pentru reviste BDI (Journal of Dentistry, Medicine and Medical Sciences);

Premii si distinctii

Premiu de Excelenta in Reumatologie, Societatea Romana de Reumatologie pentru lucrarea Model matematic de predicție a obținerii remisiunii SDAI în poliartrita reumatoidă, Trifan AE, Pomîrleanu C, Miu S, ANCUTA C, comunicare orala la CNR 2014 Bucuresti, Romania;

Diploma de merit, lucrarea Terapia cu Infliximab si sarcina – o provocare a etapei moderne, Cardei M, ANCUTA C, Ancuta E, Stoica S, Zugravu G, Chirieac R, Sesiunea comunicari orale Simpozionul Conect 2008 – Remicade la puterea a 6-a, 30 mai 2008, Bucuresti, Romania;

Mentiune lucrarea Infliximab, eficacitate si tolerabilitate in artropatia psoriazica, ANCUTA C et al, sesiunea postere, Simpozionul Conect 2008 – Remicade la puterea a 6-a, 30 mai 2008, Bucuresti, Romania;

Premiul de excelenta in medicina TNL, Gala Tinerilor valori editia IV, 24 feb 2009, Iasi, Romania

Recunoastere in Marquis Who's Who; Ancuta Codrina Mihaela Irena is recognized in Marquis

Who's Who. : physician, educator, Location: Iasi; Country: Romania;

http://bios.marquiswhoswho.com/ancuta_codrina_mihaela_irena/physician_educator/8309281

Activitate didactica, cercetare stiintifica si clinica/ de asistenta medicala (vezi Lista completa de lucrari anexata)

Activitatea profesionala desfasurata in cadrul UMF “Gr.T.Popa” Iasi si in Clinica Reumatologie, Spitalul Clinic de Recuperare Iasi (integrare cu ½ norma) s-a conturat pe trei directii principale, respectiv didactica, de cercetare stiintifica si activitatea clinica. O sinteza a acestor coordonate releva urmatoarele:

articole publicate in extenso in reviste cotate ISI: (30) (11 articole in calitate de autor principal; 19 articole coautor) (vezi lista completa lucrari anexata);

articole publicate in rezumat in reviste cotate ISI: (86) (42 autor principal, 44 coautor) (vezi lista completa lucrari anexata);

articole in extenso in reviste indexate in BDI: (85) (39 autor principal, 46 coautor) (vezi lista completa lucrari anexata);

articole in rezumat in reviste indexate in BDI sau volume manifestari stiintifice cu si fara ISBN: (76) (39 autor principal, 37 coautor) (vezi lista completa lucrari anexata);

carti, manuale, monografii: carte internationala (4 capitole); carte nationala (1 editor, 4 autor unic, 1 membru in colectiv de autori, 13 autor capitol); (vezi lista completa lucrari anexata)

participare la manifestari stiintifice internationale si nationale: (201 prezentari) (75 comunicari orale, 126 postere): international (4 autor principal si 20 coautor), national (25 autor principal si 26 coautor) (comunicari orale); international (44 autor principal si 37coautor) national ( 23 prim autor, 22 coautor) (postere); (vezi lista completa lucrari anexata)

lector la manifestari stiintifice: 110 manifestari nationale (vezi lista completa lucrari anexata)

Curriculum vitae | Codrina Irena Mihaela ANCUTA

5 | P a g e

granturi/contracte de cercetare/ studii multicentrice: granturi internationale (14) (2 director de grant; 2 director partener national in consortiu international; 10 membru in colective internationale); granturi nationale (4) (membru in echipa grant); studii multicentrice postmarketing (14) (4 investigator principal in studii internationale; 10 investigator principal in studii nationale); studii multicentrice randomizate (53) (9 investigator principal; 44 – subinvestigator/coordonator de studiu)

citari in articole: (272) (254 ISI, 18 BDI)

Articolele/studiile in extenso in reviste din fluxul stiintific international principal si BDI, publicatiile in rezumat, participarile cu comunicari orale sau postere la manifestari stiintifica internationale si nationale, activitatea editoriala se regasesc punctate in lista completa de lucrari.

Granturi/contracte de cercetare/ studii multicentrice

Director grant international (2)

1. IASP Grant: Musculoskeletal pain academy, 2011, IASP Developing Countries Project: Initiative for improving pain education; jul2011-jul2012; (acord UMF “Gr.T.Popa” Iasi nr.12119/28.06.2011); finantare IASP 7000 USD; http://www.iasp-pain.org/Education/Content.aspx?ItemNumber=954;

http://www.musculoskeletal.pain-academy.com

Proiectul este focusat pe aspectele multivalente ale durerii musculo-scheletale, cu interpretare interdisciplinara, atat din perspectiva specialistului in reumatologie, cat si a particulatilor de definire a durerii in contextul sarcinii ce survine la o pacienta cu patologie reumatismala (prezentand punctul de vedere a obstetricianului), a patologiei musculo-scheletale ce se dezvolta la practicianul stomatolog.

2. EUSTAR Clinical Project CP34: Early Accelerated Atherosclerosis in Systemic Sclerosis (SSAS), grant EUSTAR 2011-2015; UCN-EUSTAR162 (nr.12428/30.06.2011) membri echipa cercetare: Carmen Marina Mihai, UMF Bucuresti (UCN-EUSTAR 100); Valeria Ricerri, Jose Luis Rosales-Alexander (UCN-EUSTAR 094), Patricia Carreira P (UCN-EUSTAR 023), Maria Joao Salvador (UCN-EUSTAR 068), Juan José Alegre Sancho (UCN EUSTAR 123); http://www.eustar.org/ClinicalTrial.html

Colaborarea multicentrica raportat la clarificarea profilului ATS accelerate in sclerodermia sistemica, cu explorare complexa (biomarkeri surogat biologici si imagistici), in dinamica doar pentru subgrupul de pacienti cu incadrare nationala, cu insertie de asemenea interdisciplinara; date preliminare prezentate in analiza subgroup UCN EUSTAR 162 la congrese internationale; lucrare prezentata la Congresul National de Reumatologie oct 2014, Bucuresti, Romania

ANCUTA C, Pomirleanu C, Belibou C, Grosu C, Mihai CM, Magda SL, Carreira P, Rosales-Alexander JL, Ricerri V, Salvador MJ, Chirieac R, Surrogate biomarkers for subclinical atherosclerosis in systemic sclerosis: an interim analysis of the SSAS cohort, Revista Romana de Reumatologie 2014, XXIII (supliment): 78;

Director partener national in consortiu international (2)

1. EULAR Orphan Disease Program Observational study of treatment outcome in early diffuse cutaneous systemic sclerosis; Chief Investigator Professor Ariane Herrick (University of Manchester); Funder EULAR Orphan Disease Program (Funding Reference Number R111788); Acord colaborare nr. 13517/14.07.2011 Universitatea Manchester-U.M.F. “Gr.T.Popa” Iasi (jul2011-ian2014); director proiect UMF Iasi: dr. ANCUTA Codrina; finantare EULAR ODP 312 EURO/patient; 17 pacienti inrolati (5300 Euro); http://www.ssc-esos.net/home.asp; http://www.eular.org/ (activitatea site UMF Gr.TPopa Iasi – al treilea ca si activitate de recrutare a pacientilor SSc in cadrul proiectului de cercetare)

2. International EU-funded Research Project (FP7): DEsschipher, to decipher the optimal management of systemic sclerosis, http://www.eustar.org/desscipher.html ; http://www.uni-

giessen.de/fbz/fb11/institute/klinik/rheumatologie/desscipher-en?set_language=en ; https://www.uni-

giessen.de/fbz/fb11/institute/klinik/rheumatologie/desscipher-en/about-desscipher/contributing-

centers/contributing-centers

Curriculum vitae | Codrina Irena Mihaela ANCUTA

6 | P a g e

OT 1: Prevention and treatment of digital ulcers, Marco MATUCCI-CERINIC (UNIFI), Francesco

DELGADO (LEEDS), NCT01836263;

http://clinicaltrials.gov/ct2/show/NCT01836263?term=desscipher&rank=5

OT2: Improvement of hand dysfunction by arthritis, principal investigator László CZIRJÁK,

NCT01834157, http://clinicaltrials.gov/ct2/show/NCT01834157?term=desscipher&rank=2

OT3: Prevention and treatment of interstitial lung disease (lung fibrosis), principal investigator

Gabriela RIEMEKASTEN (CHARITÉ), Christopher DENTON (UCL), NCT01858259;

http://clinicaltrials.gov/ct2/show/NCT01858259?term=desscipher&rank=1

OT4: Development and prevention of pulmonary hypertension, principal investigators: Yannick

ALLANORE, Jérôme AVOUAC (UPD), NCT01840748;

http://clinicaltrials.gov/ct2/show/NCT01840748?term=desscipher&rank=4

OT5: Development and prevention of severe heart disease, PI: Gabriele VALENTINI (UNINA2),

NCT01829126, http://clinicaltrials.gov/ct2/show/NCT01829126?term=desscipher&rank=3

Proiect de cercetare castigat si finantat prin program European FP7, ambitios prin dezvoltarea multicentrica, pe 5 directii de studiu, vazand afectarea viscerala cu relevanta vitala si impact functional si asupra calitatii vietii, aflat in stadiul de recrutare a pacientilor pe teme de interes.

Membru in colectiv international (10)

1. IASP Grant IASP Developing Countries Project: Initiative For Improving Pain Education - Grant IASP (International Association for the Study of Pain); Manager de proiect dr. Jaba Irina 05.2009-05.2010; http://www.iasp-pain.org/Education/Content.aspx?ItemNumber=954 acord UMF Iasi 8499/20.05.2009; finantare IASP 9700 USD

Publicare ghid practic de terapie a durerii cronice – participare cu doua capitol - primul cu insertie cai patofiziologice, metode de cuantificare si terapie farmacologica a durerii cronice msculocheletale, cel de-al doilea cu raportare la terapia fizicala si de reabilitare

ANCUTA C. Durerea cronica musculo-scheletala. In: Mungiu OC, Jaba IM (ed) Managementul durerii –

ghid practic (grant IASP: Initiative for Improving Pain Education), Editura “Gr.T.Popa”, UMF Iasi 2010,

ISBN: 978-973-7682-98-7 (pg 113-142);

ANCUTA C, Managementul non-farmacologic al durerii cronice musculo-scheletale. In: Mungiu

OC, Jaba IM (ed) Managementul durerii – ghid practic (grant IASP: Initiative for Improving Pain

Education), Editura “Gr.T.Popa”, UMF Iasi 2010, ISBN: 978-973-7682-98-7 (pg 206-210);

2. PROTOCOL QUEST-RA 2009-2011: Quantitative Patient Questionnaire Monitoring in Standard Clinical Care of Patients with Rheumatoid Arthritis (QUEST-RA), Manager de proiect Tuulikki SOKKA (Finland), 2009-2011 (grant cu finantare internationala si locala Abbvie)

3. PROTOCOL QUEST-RA 2013-2014: Treating Rheumatoid Arthritis to Target: Are Recommendations met? A Multinational Study of Patients with Rheumatoid Arthritis who Receive Usual Care in 33 Countries; Manager de proiect Tuulikki SOKKA (Finland), 2013-2014 (aviz nr 6680/01.04.2013) (grant cu finantare internationala si locala Abbvie)

Protocol de studiu complex, cu incadrare multinationala (33 tari) si multicentrica, cu o cuantificare atat de moment (pacienti consecutivi) a normelor de practica cotidiana in poliartrita reumatoida cu specificitate nationala, dar si cu evaluare in dinamica (vizite predefinite in cadrul studiului), cu raportare la recomandarile T2T formulate de EULAR.

Pt protocoalele 2 si 3, rezultatele au fost diseminate in cadrul manifestari EULAR si ACR, dar si prin numeroase publicatii in fluxul international ISI. Intre acestea, participarea directa in:

Grøn et al, The association of fatigue, comorbidity burden, disease activity, disability and gross

domestic product in patients with rheumatoid arthritis. Results from 34 countries participating in

the Quest-RA program. Clinical and Experimental Rheumatology [2014] (PMID:25327997); Clin Exp

Rheumatol. 2014 Nov-Dec;32(6):869-77. Epub 2014 Oct 20 IF=2.973;

http://europepmc.org/abstract/med/25327997;; http://www.ncbi.nlm.nih.gov/pubmed/25327997

Curriculum vitae | Codrina Irena Mihaela ANCUTA

7 | P a g e

Khan NA, ANCUTA C, Patient's global assessment of disease activity and patient's assessment of

general health for rheumatoid arthritis activity assessment: are they equivalent? Ann Rheum Dis.

2012 Dec;71(12):1942-9. doi: 10.1136/annrheumdis-2011-201142. Epub 2012 Apr 24. IF=9.11;

http://ard.bmj.com/content/71/12/1942.short

Khan NA, ANCUTA C, Determinants of discordance in patients' and physicians' rating of rheumatoid

arthritis disease activity. Arthritis Care Res (Hoboken). 2012 Feb;64(2):206-14. doi: 10.1002/acr.20685.

IF=4.039; http://onlinelibrary.wiley.com/doi/10.1002/acr.20685/full

Sokka T, QUEST-RA. Work disability remains a major problem in rheumatoid arthritis in the 2000s:

data from 32 countries in the QUEST-RA study. Arthritis Res Ther. 2010;12(2):R42. doi: 10.1186/ar2951.

Epub 2010 Mar 12.; IF=4.357; http://www.ncbi.nlm.nih.gov/pubmed/20226018

Participare in 6 protocoale in colaborare multinationala multicentrica EUSTAR in cadrul UCN EUSTAR 162, si anume:

4. EUSTAR Project CP18: Digital Ulcers secondary to Systemic sclerosis AC-052-513 - grant EUSTAR Research group and Actelion EUSTAR (Project leader: Prof. Ulrich Walker; Actelion Project leader: Monika Brand; Project manager: Dr Rebecca Hollaender) (Nov 2009 – Oct 2010); http://www.eustar.org/ClinicalTrial.html

5. EUSTAR Clinical Project: Very Early Diagnosis of Systemic Sclerosis VEDOSS, 2010-2015 (2020), , PROJECT manager: prof dr. Marco Matucci Cerinic ; aviz nr. ; http://www.eustar.org/Vedoss.html (6681/01/04.2013)

Minier et al (EUSTAR co-workers), Preliminary analysis of the Very Early Diagnosis of Systemic

Sclerosis (VEDOSS) EUSTAR multicentre study: evidence for puffy fingers as a pivotal sign for

suspicion of systemic sclerosis. Ann Rheum Dis. 2014 Dec;73(12):2087-93. doi: 10.1136/annrheumdis-

2013-203716. Epub 2013 Aug 12.; IF=9.270; http://www.ncbi.nlm.nih.gov/pubmed/23940211

6. EUSTAR Clinical Project: MEDS; http://www.eustar.org/MedsOnline.html (aviz nr 12528/10.07.2009)

Meier et al EUSTAR Co-authors. Update on the profile of the EUSTAR cohort: an analysis of the EULAR

Scleroderma Trials and Research group database. Ann Rheum Dis. 2012 Aug;71(8):1355-60. doi:

10.1136/annrheumdis-2011-200742. Epub 2012 May 21.; IF=9.111;

http://www.ncbi.nlm.nih.gov/pubmed/22615460

Elhai M et al (EUSTAR co-authors), A gender gap in primary and secondary heart dysfunctions in

systemic sclerosis: a EUSTAR prospective study. Ann Rheum Dis. 2014 Oct 23. pii: annrheumdis-2014-

206386. doi: 10.1136/annrheumdis-2014-206386. [Epub ahead of print]; . IF=9.27;

http://ard.bmj.com/content/early/2014/10/31/annrheumdis-2014-206386.short

Maurer B et al, EUSTAR co-authors. Prediction of worsening of skin fibrosis in patients with diffuse

cutaneous systemic sclerosis using the EUSTAR database. Ann Rheum Dis. 2014 Jun 30. pii:

annrheumdis-2014-205226. doi: 10.1136/annrheumdis-2014-205226. [Epub ahead of print]; IF=9.27;

http://ard.bmj.com/content/early/2014/07/07/annrheumdis-2014-205226.short;

http://www.ncbi.nlm.nih.gov/pubmed/24981642

7. EUSTAR Clinical Project IMPRESS 2: International Multi-centric Prospective study on pregnancy in systemic sclerosis, Directori proiect: Monika Ostensen University of Trondheim Norway, Angela Tincani University of Brescia Italy, Antonio Brucato, Ospedale Reuniti Bergamo Italy. oct 2013; aviz 19616/07.10.2013

http://www.eustar.org/ClinicalTrial.html

8. EUSTAR Clinical Project CP11: Prevalence and clinical associations of capillaroscopic scleroderma patterns in the EULAR Scleroderma Trial And Research group (EUSTAR) database of patients with systemic sclerosis. Project Francesca Ingegnoli, (EUSTAR UCN 110), 2011; http://www.eustar.org/ClinicalTrial.html

Ingegnoli F et al (EUSTAR co-authors), Nailfold capillaroscopy in systemic sclerosis: data from the

EULAR scleroderma trials and research (EUSTAR) database. Microvasc Res. 2013 Sep;89:122-8. doi:

10.1016/j.mvr.2013.06.003. Epub 2013 Jun 17.; IF=2.432

http://www.sciencedirect.com/science/article/pii/S0026286213000939

Curriculum vitae | Codrina Irena Mihaela ANCUTA

8 | P a g e

9. EUSTAR Clinical Project CP14: Biologics in systemic sclerosis patients treated with Rituximab. If you have SSc patients treated with Rituximab; PI O Distler, UCN 006, Zurich; http://www.eustar.org/ClinicalTrial.html

Jordan S, Distler JH, Maurer B, Huscher D, van Laar JM, Allanore Y, Distler O; on behalf of the EUSTAR

Rituximab study group. Effects and safety of rituximab in systemic sclerosis: an analysis from the

European Scleroderma Trial and Research (EUSTAR) group. Ann Rheum Dis. 2014 Jan 17. doi:

10.1136/annrheumdis-2013-204522. [Epub ahead of print]; . IF=9.270;

http://ard.bmj.com/content/early/2014/01/17/annrheumdis-2013-204522.short

10. PROTOCOL IRIS: International Recommendation Implementation Study – a multinational observational study to investigate the impact of recent treatment recommendations for the treatment of patients with rheumatoid arthritis using web-based patient monitoring (METEOR); primary investigator Robert B.M. Landewé (22.05.2013)

Protocol international de monitorizare a pacientului cu PR in cadrul recomandarilor T2T si insertie in registru electronic, cu potential de dezvoltare a multiple publicatii in conditiile analizei multidimensionale a bolii raportat la activitate, calitatea vietii, practice terapeutice.

Membru colectiv national (4)

1. GRANT CNCSIS: Platforma de cercetari fizio-farmacologice si clinice asupra mecanismelor durerii oncologice si non-oncologice; cod CNCSIS 68; Contract 11/15.09.2006; 2006-2008; director proiect OC MUNGIU (membru in echipa de cercetare) (finantare CNCSIS) in cadrul Centrului pentru Studiul si Terapia Durerii de la Universitatea de Medicina si Farmacie "Grigore T. Popa” Iasi;

http://www.umfiasi.ro/Cercetare/CentreDeCercetare/Pages/default.aspx

http://www.algezio.ro/categorie/Cercetare_025/PLATFORMA_DE_CERCETARI_FIZIOFARMACOLOGICE_SI_CLINICE_ASUPRA_MECANISMELOR_DURERII_NONONCOLOGICE_SI_ONCOLOGICE_%28Cod_CNCSIS:_68%29_078.html

proiect de cercetare cu finantare CNCSIS, ce a pus bazele cercetarii aprofundate in domeniul durerii musculoscheletale, cu predilectie durerea inflamatorie, colaborarii interdisciplinare; puncte de reper: infiintarea Centrului de Algeziologie Clinica, achizitie VICON, aparat de analiza computerizata a biomecanicii mersului; grup de studiu dezvoltat ulterior cu activitate si in prezent pe durerea inflamatorie din boala reumatismala cu determinsm imun si insertia terapiei biologice in acest context (sub coordonarea subsemnatei); diseminare rezultate manifestari stiintifice si publicatii ISI;

2. PROIECT POSCCE-A2-O2.2.1-2007-1+Capacitati-I-2007-2, IMPACT IV sesiunea Sept 2007: Centru de cercetare a lupusului eritematos sistemic si bolilor autoimune inrudite (CCLESAI), 2007-2008, proiect finantat (ID 1071); director proiect prof Chirieac R; (director stiintific in echipa proiectului) http://www.poscce.research.ro/ro/articol/1737/fonduri-structurale-istoric-impact-sesiune-impact-iv-septembrie-2007

3. POSCCE A2-O2.2.1-2009-4 Operatiunea 2.2.1 Centru de cercetare a lupusului eritematos sistemic si bolilor autoimune inrudite, Director stiintific, http://www.finantare.ro/stire-15020-Rezultate-preliminare-evaluare-competitia-POS_CCE-A2_O221-_-2009.html (proiect depus la competitia mentionata urmarind dezvoltarea infrastructurii de cercetare pe domeniul lupusului eritematis sistemic; desi punctajul obtinut a situat proiectul intre cele admise, cu un scor egal pentru 4 dintre acestea, nu a beneficiat de finantare)

4. PROIECT POSDRU 81/3.2/S/55648, Formare profesionala pentru implementarea noilor tehnologii in sistemul de sanatate PERFORMED, director proiect – prof dr HD Bolosiu, UMF I Hatieganu Cluj-Napoca, 2010-2013, competitie, fonduri 5.000.000 EURO (realizarea si prezentarea cursuri, Sesiunea de formare NE, http://performed.ro/; http://performed.ro/simpozioane/sesiunea-de-formare-8-nord-est-iasi-10-13-septembrie-2013/

Studii multicentrice, PMOS si de faza II-III (randomizate, controlate)

Curriculum vitae | Codrina Irena Mihaela ANCUTA

9 | P a g e

Investigator principal PMOS: nationale (4), internationale (10), si trialuri randomizate (9)

1. PROTOCOL ML25228 REPEAT: Studiu observational post-marketing cu Mabthera prescris pacientilor TNF-

IR, pentru evaluarea eficacitatii si sigurantei curelor repetate in practica medicala clinica de rutina

(Repeated Courses in routine Clinical Practice) (2012-2013) sponsor Roche

2. PROTOCOL ML25332 STONE: Studiu observational post-marketing cu Ro-actemra (tocilizumab) prescris

pacientilor DMARD-IR pentru evaluarea eficacitatii si sigurantei adminstrarii in practica clinica de rutina;

sponsor Roche (2009-2011)

3. PROTOCOL ML27953 FAST2 SWITCH: Studiu non-interventional prospective multicentric pentru a evalua

eficacitatea si siguranta rituximab la pacienti cu artrita reumatoida active care au avut un raspuns inadecvat

sau intolerant la un agent anti-TNF (2011) sponsor Roche

4. Protocol ELOCVENT – Evaluarea impactului osteoporozei postmenopauza asupra calitatii vietii pacientelor

– studiu observational sponsor Servier; 04.2008-07.2008

5. PROTOCOL BEL115014 SESAME: Systemic Lupus Erythematosus in CEE Settings: Romania, Poland,

Hungary. An insight on Medical, Economic and Social Burden (2011-2012); sponsor: GSK.

6. PROTOCOL P10-599: An observational study of the impact of the anti-cyclic citrullinated peptide antibody

(anti-CCP) status on the management of patients with early rheumatoid arthritis (study HU-08-02): a multi-

country, multi-center, post-marketing observational study in the routine clinical use (2010-2011); sponsor:

Abbott.

7. PROTOCOL P10-919 EviraEAST: Evaluation of clinical outcome, treatment compliance and tolerability of

Humira (adalimumab) in patients with active Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing

Spondylitis in Eastern European countries: a multi-country, multicenter post-marketing observational study

in routine clinical use (2009-2011) (PMOS-CE-08-01); sponsor: Abbott.

8. PROTOCOL PMOS P10-733 DEXA: Evaluation of the Role of Adalimumab on extra-articular manifestation-

bone metabolism and bone mineral density in patients with active Rheumatoid Arthritis (2011-2012) (centre

42146); sponsor: Abbott.

9. PROTOCOL P12-768: Multi-country post-marketing observational study on maintenance of effectiveness of

adalimumab (Humira) in patients with ankylosing spondylitis and psoriatic arthritis – a multi-country

observational study in routine use in Central and Eastern Europe (nov 2011-2012 ); sponsor Abbott;

10. PROTOCOL P13-682 IDEA: Impactul adalimumab (Humira) ca terapie asupra utilizării anumitor resurse

legate de îngrijirea sănătății și asupra concediului medical la pacienții cu spondilită anchilozantă, în practica

clinică curentă (2012-2014), sponsor Abbott;

11. PROTOCOL P13‐683 PACE: Evaluarea activitatii fizice la pacientii cu poliartrita reumatoida tratati cu

adalimumab in practica clinica de rutina (PACE)- studiu observational postmarketing, multinational,

multicentric privind practica curentă în Europa Centrală și de Est (2012-2014); sponsor Abbott;

12. PROTOCOL IMM11-0138 ALIGN: Epidemiological/HEOR Study– Multi-country, cross sectionAL study to

determine patient specIfic and General beliefs towards medicatioN and their treatment compliance to

selected systemic therapies in chronic inflammatory diseases (IMID) (2012-2013); sponsor Abbott;

13. PROTOCOL 10297 PROOF: Pacienţi cu spondiloartrită axială: registru multi-naţional al caracteristicilor

clinice, inclusiv progresia radiologică, şi al poverii bolii pe parcursul a 5 ani în condiții reale (2014-2019);

sonsor Abbvie;

14. PROTOCOL IMM-12-0118: Evaluation of management of patients with early rheumatoid arthritis (RA)

in routine clinical practice based on Treat to Target (T2T) principles, (2014-2015), sponsor Abbvie

15. PROTOCOL IM 128-027: Studiu de faza 2 multicentric randomizat dublu orb controlat placebo de evaluate

a sigurantei si eficacitatii BMS-913699 vs placebo adminstrat pe fondul standardelor de ingrijire

restrictionat, ca tratament al subiectilor cu lupus eritematos sistemic active; sponsor Bristoll Myers Squibb

International Corporation Belgia; Investigator Principal (2014)

16. PROTOCOL A3921187 (9002-0249): A Phase 3b/4 randomized double blind study of 5 mg of Tofacitinib

with and without Methotrexate in comparison to Adalimumab with Methotrexate in subjects with moderately

to several active rheumatoid arthritis. Investigator principal (2014)

Curriculum vitae | Codrina Irena Mihaela ANCUTA

10 | P a g e

17. PROTOCOL G0-VIBRANT. COD CNTO148PSA3001 A multi-centric, randomized, double blind placebo

controlled trial of golimumab, an anti TNF monoclonal antibody, administered intravenously, in subjects with

active psoriatic arthritis. Phase3. Investigator principal (2014)

18. PROTOCOL G0-ALIVE. COD CNTO148AKS3001 A multi-centric, randomized, double blind placebo

controlled trial of golimumab, an anti TNF monoclonal antibody, administered intravenously, in subjects with

active ankylosis spondylitis.Phase3. Investigator principal (2014)

19. PROTOCOL GLASS: A multi-center, randomized double-blind parallel group study on the therapeutic efficacy

and safety of febuxostat (taken once daily) and the therapeutic efficacy and safety of allopurinol on serum

urate concentration in subjects suffering from hyperuricemia and gout (MEIN/11/FEN-Gou/001; CRO

InnoPharma SRL, Sponsor MIOL, 2014-2015

20. PROTOCOL A9391010: a phase 2, randomized, double blind assessment of efficacy and safety of pf-

04171327 (1, 5, 10, 15 mg dose, daily) compared to 5 mg and 10 mg prednisone daily and placebo daily in

subjects with rheumatoid arthritis over an 8 week period followed by a 4 week period of tapering of study

drug; intermediar; Parexel; sponsor: Pfizer; Investigator principal (2014)

21. PROTOCOL B1801315: A randomized, double-blind placebo-controlled study of the maintenance of efficacy

of etanercept plus DMARD(s) compared with DMARD(s) alone in subjects with rheumatoid arthritis after

achieving an adequate response with etanercept plus DMARD(s); CRO: Parexel; sponsor: Pfizer Investigator

principal (2013)

22. PROTOCOL AB 06012: A phase 2b/3 study to evaluate efficacy and safety of masitinib in comparison to

methotrexate in patients with active rheumatoid arthritis with inadequate response to methotrexate or to

any disease-modifying antirheumatic drug; CRO: HT Research RO; sponsor AB Science; Investigator

principal (2013)

23. PROTOCOL PRINT Study, TcLand: Validation study of RA-INF-Dx as multigene molecular in vitro blood test

intended to aid in the identification of patients with rheumatoid arthritis who are unlikely to shown an initial

response to infliximab and methotrexate combination therapy (”Predict non-response to Infliximab therapy

study”) (2011-2012); sponsor: TcLand Expression; CRO: Premier Research Investigator principal (2012);

Subinvestigator (membru in echipa proiectului) sau coordonator de studiu (44)

1. PROTOCOL M12-965 EudraCT 2014-001471-31: Phase 2, Multicenter, Open-Label Extension (OLE) Study

with ABT-122 in Rheumatoid Arthritis Subjects Who Have Completed the Preceding M12-963 Phase 2

Randomized Controlled Trial (RCT) Subinvestigator (2014-in desfasurare); sponsor Abbvie; (Investigator

principal prof Chirieac R) (adeverinta 2/05.01.2015)

2. PROTOCOL EFC 10832: A randomized, double-blind, parallel, placebo-controlled study assessing the efficacy

and safety of sarilumab added to non-biologic DMARD therapy in patients with rheumatoid arthritis who are

inadequate responders to or intolerant of TNF-α antagonists; CRO: Covance; sponsor: Sanofi;

Subinvestigator (2013 – 2014); (Investigator principal prof Chirieac R) (adeverinta 6/05.01.2015)

3. PROTOCOL CD-IA-MEDI-546-1013: A phase 2, randomized study to evaluate the efficacy and safety of

medi-546 in subjects with systemic lupus erythematosus; CRO: INC Research; sponsor: Medimmune;

Subinvestigator (2013 – in desfasurare); (Investigator principal prof Chirieac R) (adeverinta

7/05.01.2015)

4. PROTOCOL CNTO136ARA3002: A study of CNTO 136 (sirukumab), administered subcutaneously, in

patients with active rheumatoid arthritis despite disease-modifying antirheumatic drug (DMARD) therapy

(SIRROUND); CRO: Parexel; sponsor: Janssen; Subinvestigator (2013 – in desfasurare); (Investigator

principal prof Chirieac R) (adeverinta 8/05.01.2015)

5. PROTOCOL RA 0055: A multi-center, randomized, double-blind, placebo-controlled study to evaluate the

efficacy and safety of certolizumab pegol in combination with methotrexate for inducing and sustaining

clinical response in the treatment of DMARD-naïve adults with early active rheumatoid arthritis; CRO:

Parexel; sponsor: UCB Subinvestigator (2013 – 2014); (Investigator principal prof Chirieac R) (adeverinta

9/05.01.2015)

6. PROTOCOL I4V-MC-JADV a randomized, double-blind, placebo and active-controlled, phase 3 study

evaluating the efficacy and safety of baricitinib in patients with moderately to severely active rheumatoid

Curriculum vitae | Codrina Irena Mihaela ANCUTA

11 | P a g e

arthritis who have had an inadequate response to methotrexate therapy; CRO: ICON; sponsor: Eli Lilly;

Subinvestigator (2013 – in desfasurare); (Investigator principal prof Chirieac R) (adeverinta

10/05.01.2015)

7. PROTOCOL I4V-MC-JADY: a phase 3, multicenter study to evaluate the long-term safety and efficacy of

baricitinb in patients with rheumatoid arthritis; CRO: ICON; sponsor: Eli Lilly; Subinvestigator (2013 – in

desfasurare); (Investigator principal prof Chirieac R) (adeverinta 11/05.01.2015)

8. PROTOCOL H9B-MC-BCDP: a phase 3, multicenter, open label study to evaluate the long-term safety and

efficacy of LY2127399 in patients with Rheumatoid Arthritis; CRO: Quintiles; sponsor Eli Lilly; 2012-2013;

Subinvestigator; (Investigator principal prof Chirieac R) (adeverinta 12/05.01.2015)

9. PROTOCOL H9B-MC-BCDM: a phase 3, multicenter, randomized, double blind placebo controlled study to

evaluate the efficacy and safety of sc LY2127399 in patients with moderate to severe Rheumatoid Arthritis

who had an inadequate response to methotrexate therapy; CRO: Quintiles; sponsor: Eli Lilly;

Subinvestigator (2012-2013); (Investigator principal prof Chirieac R)

10. PROTOCOL H9B-MC-BCDT: a phase 3, multicenter, randomized, double blind placebo controlled study to

evaluate the efficacy and safety of sc LY2127399 in patients with Systemic Lupus Erythematosus; CRO:

Parexel; sponsor: Eli Lilly; Subinvestigator (2012-2013); (Investigator principal prof Chirieac R)

(adeverinta 13/05.01.2015)

11. PROTOCOL H9B-MC-BCDO: a phase 3, multicenter, randomized, double blind placebo controlled study to

evaluate the efficacy and safety of sc LY2127399 in patients with Rheumatoid Arthritis with or without

background of Disease Modifying Anti-Rheumatic Drug(DMARD) therapy; CRO: Quintiles; sponsor: Eli Lilly;

Subinvestigator (2012-2013); (Investigator principal prof Chirieac R) (adeverinta 14/05.01.2015)

12. PROTOCOL H9B-MC-BCDX: a phase 3b, multicenter, open-label study to evaluate the long-term safety and

efficacy of subcutaneous LY2127399 in patients with systemic lupus erythematosus (SLE) (illuminate-x); CRO:

Parexel; sponsor: Eli Lilly; Subinvestigator (2012-2013); (Investigator principal prof Chirieac R)

(adeverinta 15/05.01.2015)

13. PROTOCOL Novartis CAIN457F2306: A randomized double-blind placebo-controlled multicenter study,

Novartis, Subinvestigator (2012-2013); (Investigator principal prof Chirieac R)

14. PROTOCOL WA22762: A randomized, double-blind, parallel group study of the safety and effect on clinical

outcome of tocilizumab SC versus tocilizumab IV, in combination with traditional disease modifying anti-

rheumatoid arthritis drugs (DMARDs), in patients with moderate to severe active rheumatoid arthritis; CRO:

Comac sponsor Hoffman La Roche, Sub-investigator, 2010 -2104; Subinvestigator(Investigator principal

prof Chirieac R) (adeverinta 16/05.01.2015)

15. PROTOCOL ENTRACTE: A clinical outcomes study to evaluate the effects of IL-6 receptor blockade with

tocilizumab (TCZ) in comparison with etanercept (ETA) on the rate of cardiovascular events in patients with

moderate to severe rheumatoid arthritis (RA);CRO: Quintiles; sponsor : Hoffmann-LaRoche, Subinvestigator,

(Investigator principal prof Chirieac R) (2012- in desfasurare) (adeverinta 17/05.01.2015)

16. PROTOCOL I4V-MC-JADA: A randomized, double blind placebo controlled, dose ranging, parallel group,

phase 2b study in patients with active RA on MTX background therapy spondor: Eli Lilly; CRO Parexel; Sub-

investigator, 2010 - 2014 (Investigator principal prof Chirieac R) (adeverinta 18/05.01.2015)

17. PROTOCOL Protocol I1F-MC-RHAK: studiu faza II cu doze variabile, subcutanate multiple de LY2439821

(Ac anti IL-17) la pacienti cu artrita reumatoida activa care urmeaza tratament concomitent cu DMARD;

sponsor: Eli Lilly; Sub-investigator, 2010 - 2013 (Investigator principal prof Chirieac R) (adeverinta

19/05.01.2015)

18. PROTOCOL A phase II, randomized, double-blind, controlled study to evaluate the immune responses, safety

and clinical efficacy of three doses of Neovacs’ TNF Kinoid in adult patients with rheumatoid arthritis who

have relapsed despite anti-TNF- biological therapy-sponsor Neovasc; CRO Genexion, Sub-investigator,

2010 - 2011

19. PROTOCOL P06129 GO-MORE: Un studiu cu design deschis (open-label),pentru a evalua adaugarea de

Golimumab Subcutanat (GLM) la terapia conventionala cu medicamente modificatoare de boala (DMARD) la

pacientii cu Artrita Reumatoida naivi la terapia biologica (Partea 1) urmata de un studiu randomizat ce

evalueaza valoarea terapiei combinate cu GLM administrat intravenous si subcutanat in scopul inducerii si

Curriculum vitae | Codrina Irena Mihaela ANCUTA

12 | P a g e

mentinerii remisiunii(Partea 2); MSD, Sub-investigator, 2010 – 2012 (Investigator principal prof Chirieac

R) (adeverinta 20/05.01.2015)

20. PROTOCOL TRU-015-3206K1-2203-WW: a randomized, parallel, double-blind, placebo controlled dose

regimen finding study to evaluate the safety and efficacy of TRU-015 in subjects with active seropositive

Rheumatoid Arthritis on a stable background of methotrexate; sponsor & CRO: Wyeth; Sub-investigator,

2009-2011 ; (Investigator principal prof Chirieac R)

21. PROTOCOL A3921024: A long term, open label follow up study of CP-690.550, a moderately selective Janus

kinase 3 inhibitor, for treatment of Rheumatoid Arthritis. Sponsor & CRO: Pfizer; Sub-investigator, 2009-in

desfasurare (Investigator principal prof Chirieac R) (adeverinta 21/05.01.2015)

22. PROTOCOL RADAR: PROTOCOL P05320, Observational Trial on the value of diagnostic criteria in the diagnosis of spinal spondylarthropathies in patients with chronic low back pain; Recognizing and

Diagnosing Ankylosing Spondylitis Reliably; sponsor MSD; Sub-investigator, 2009-2010 (Investigator

principal prof Chirieac R) (adeverinta 22/05.01.2015)

23. PROTOCOL BT971: studiu randomizat, controlat placebo, dublu orb cu esaladarea dozei pentru a evalua

eficacitatea, siguranta, si tolerabilitatea medicatiei de studiu BT971 la pacienti cu artrita reumatoida cu

tratament concomitent cu MTX; sponsor: Biotest AG Germany; CRO: IFE Romania, Sub-investigator, 2009-

2010 ; (Investigator principal prof Chirieac R) (adeverinta 23/05.01.2015)

24. PROTOCOL H8C-MC-LQBG: A Phase 2 Study of the Effects of LY545694, an iGluR5 Antagonist, in the

Treatment of Subjects With Osteoarthritis Knee Pain; sponsor: Eli Lilly; Sub-investigator, 2008-2009;

(Investigator principal prof Chirieac R) (adeverinta 24/05.01.2015)

25. PROTOCOL WA20496: A randomized, double-blind, parallel group, international study to evaluate the

safety and efficacy of Ocrelizumab given as a single infusion or dual infusion compared with placebo in

patients with active Rheumatoid Arthritis who have an inadequate response to methotrexate therapy;

Sponsor: Hoffmann La Roche; CRO: Quintiles Romania; subinvestigator, 2008-2011; (Investigator

principal prof Chirieac R) (adeverinta 25/05.01.2015)

26. PROTOCOL ROB 803-09-002: a phase II, randomized, double-blind, multicenter placebo-controlled, dose-

ranging, parallel study group to evaluate the efficacy and safety of orally administered Rob 803 when added

to stable MTX in patients with moderate or severe active Rheumatoid Arthritis; Sponsor: Oxypharma; CRO:

Pharm-Olam; Sub-investigator, 2008-2009 ; (Investigator principal prof Chirieac R) (adeverinta

26/05.01.2015)

27. PROTOCOL LJP 394-90-14: A randomized, double-blind, placebo controlled, three arm, parallel group,

multicenter, multinational safety and efficacy trial of 300 mg and 900 mg of Abetimus Sodium in SLE patients

with a history of renal disease; sponsor: La Jolla International; CRO: Pharm-Olam; subinvestigator, 2008-

2009; (Investigator principal prof Chirieac R) (adeverinta 27/05.01.2015)

28. PROTOCOL WA20499: A randomized, double-blind placebo controlled parallel group multicenter study to

evaluate the efficacy and safety of two doses of Ocrelizumab in patients with active SLE; Sponsor: Hoffmann-

La Roche Ltd/ Genetech Inc; CRO: Quintiles Romania, subinvestigator, 2008-2009; (Investigator principal

prof Chirieac R) (adeverinta .01.2015)

29. PROTOCOL IP-004: studiu faza IIb, multicentric, randomizat, dublu orb, placebo-contolat pentru evaluarea

sigurantei, tolerantei si eficacitatii a doua doze de studiu IPP 201101 subcutanat plus terapia standard, in

comparatie cu placebo la pacientii cu LES; sponsor: Immupharma; CRO: Genexion; Sub-investigator, 2008-

2009 ; (Investigator principal prof Chirieac R) (adeverinta 28/05.01.2015)

30. PROTOCOL A3921035: a phase II B, randomized, double blind, placebo controlled active comparator,

multicenter study to compare 5 dose regiments of CP-690.550 and adalimumab versus placebo, administered

for 6 months in the treatment of subjects with active Rheumatoid Arthritis. Sponsor & CRO: Pfizer, Sub-

investigator, 2008-2009 ; (Investigator principal prof Chirieac R) (adeverinta 29/05.01.2015)

31. PROTOCOL D1520C00001: a randomized, double-blind (with open comparator Etanercept), placebo-

controlled, phase IIB multicenter study to evaluate the efficacy of 4 doses of AZD9056 administered for 6

months on the signs and symptoms of Rheumatoid Arthritis in patients with active disease receiving

background MTX or Sulphasalasine; sponsor: Astra-Zeneca; CRO: Verum; Sub-investigator, 2008-2009 ;

(Investigator principal prof Chirieac R) (adeverinta 30/05.01.2015)

Curriculum vitae | Codrina Irena Mihaela ANCUTA

13 | P a g e

32. PROTOCOL MDX 1100-04: a phase II, multi-dose, double-blind, placebo controlled, randomized, multicenter

study of MDX-1100 (anti CXCL 10 Human Monoclonal Antibody) in patients with active Rheumatoid Arthritis;

sponsor: Medarex; CRO: PSI Pharma; Sub-investigator, 2008-2009; (Investigator principal prof Chirieac

R) (adeverinta 31/05.01.2015)

33. PROTOCOL ACT5488: Activity and safety of oral administration of SSR150106XB for the reduction of

inflammation in patients with active rheumatoid arthritis; :a 4 week, multicenter, randomized, double-blind,

placebo-controlled parallel group study of 90 mg administered once daily and 90mg once every other day;

Sponsor Sanofi-Aventis; CRO: I3 research; subinvestigator, 2007-2008; (Investigator principal prof

Chirieac R) (adeverinta 32/05.01.2015)

34. PROTOCOL P04422: A randomized, multicenter, international open label study of infliximab plus

methotrexat versus methotrexat alone for the treatment of methotrexate naive subjects with active psoriatic

arthritis; sponsor & CRO: Schering Plough Central East AG; faza IV; subinvestigator, 2007-2008;

(Investigator principal prof Chirieac R) (adeverinta 33/05.01.2015)

35. PROTOCOL: A phase 2 multicenter randomized double-blind placebo-controlled parallel-group dose finding

study of the safety and efficacy of daily CF101 administered orally when added to weekly methotrexate in

patients with active rheumatoid arthritis; Sponsor Can-fite Bio-Pharma Ltd; CRO: Pharm Olam

International; subinvestigator 2006-2007; (Investigator principal prof Chirieac R) (adeverinta

37/05.01.2015)

36. PROTOCOL WA17047: A randomized, phase 3, controlled, double-blind, parallel-group, multicenter study to

evaluate the safety and efficacy of rituximab in combination with methotrexat compared to methotrexate

alone, in methotrexat –naïve patients with active rheumatoid arthritis; Sponsor: Hoffmann-La Roche

Genentech; CRO: Parexel, subinvestigator 2006-2010; (Investigator principal prof Chirieac R) (adeverinta

36/05.01.2015)

37. PROTOCOL P1-0205: Efficacy and safety of FASU1 versus FASU2 in a 180 day study treatment in patients

with osteoarthritis of the knee; Sponsor Laboratoires Expascience; CRO: CRC Pharmaceuticals,

subinvestigator 2006-2007; (Investigator principal prof Chirieac R) (adeverinta 35/05.01.2015)

38. PROTOCOL F1J-MC-HMEP. Duloxetine 60 to 120mg versus placebo in the treatment of patients with

Osteoarthritis knee pain; sponsor si CRO: Eli Lilly Romania SRL; subinvestigator 2006-2007; (Investigator

principal prof Chirieac R)

39. PROTOCOL D1520C05287. A randomized double-blind, placebo-controlled, parallel group, ascending dose

study to assess the activity, safety and tolerability of 2 doses of AZD9056 for 4 weeks in patients with active

rheumatoid arthritis receiving methotrexate and/or sulphasalazine, phase II; sponsor Astra Zeneca; CRO

Parexel International SRL, subinvestigator, 2005-2006; (Investigator principal prof Chirieac R)

(adeverinta 34/05.01.2015)

40. PROTOCOL MDT3-005. A two-arm study comparing the analgesic efficacy and safety of Tramadol HCl once-

a-day versus placebo for the treatment of pain due to osteoarthritis of the knee; CRO: Parexel International;

coordonator studiu, 2005-2006; (Investigator principal prof Chirieac R) (adeverinta 38/05.01.2015)

41. PROTOCOL H4Z-MC-GJAD. Effects of Arzoxifene on vertebral fracture incidence and on invasive breast

cancer incidence in postmenopausal; women with osteoporosis or with low bone density; Sponsor Ely Lilly

and Company; CRO: Quintiles Romania; subinvestigator, 2004-2009; (Investigator principal prof Chirieac

R) (adeverinta 39/05.01.2015)

42. PROTOCOL MI-CP100: A phase II, randomized, double -blind study to evaluate the effects of MEDI-522, a

humanized monoclonal antibody to integrin alpha V beta 3 on disease activity and progression of joint

damage in patients with active rheumatoid arthritis sub-optimally responding to methotrexat; sponsor

Medimmune; CRO: PSI Pharma Support Romania SRL; coordonator studiu, 2003-2004; (Investigator

principal prof Chirieac R)

43. PROTOCOL Studiu multicentric, de faza III, randomizat, asupra tolerabilitatii Tramadol la pacienti cu atroza

de genunchi; Parexel International, coordonator studiu, 2003-2004; (Investigator principal prof Chirieac

R)

44. PROTOCOL Studiu multicentric, de faza III, randomizat, dublu orb, placebo-controlat asupra tolerabilitatii

gastro-intestinale a combinatiei terapeutice diclofanac-misoprostol (ArthrotecR) la pacienti cu atroza de

Curriculum vitae | Codrina Irena Mihaela ANCUTA

14 | P a g e

genunchi; coordonator studiu, 1998-1999; (Investigator principal prof Chirieac R) (adeverinta

40/05.01.2015)

Burse de tip mobilitate pentru pregatire profesionala, obtinute prin competitie (evaluarea CV, scrisoare de motivatie)

3rd Annual Meeting of the Lupus Academy, 7-9 March 2014 Berlin, Germany (bursa)

14th EULAR Intermediate Sonography Course, 10-13 June 2007, Sitges, Barcelona, Spania (bursa studiu EULAR)

9th EULAR Sonography Course (from introductory to advanced practical course on musculoskeletal sonograhy), 9-12 Dec 2004, Paris, France (bursa de studiu EULAR);

1st European Course–Capillaroscopy and Rheumatic Diseases, 10-12 Sep 2004, Genova, Italy (bursa EULAR);

6th EULAR Postgraduate Course in Rheumatology, 18-27 June 2000, Nice, Franta (sub patronaj EULAR) (bursa de studiu EULAR);

Lucrari de diploma indrumate: 74 lucrari licenta Facultatea de Medicina (42 licenta in limba engleza); 14 lucrari indrumate Faculatatea Bioinginerie; 3 lucrari in dubla coordonare cu cadru didactic disciplina Ergonomie, Facultatea Stomatologie (web-site-ul bibliotecii UMF “Gr.T.Popa” Iasi)

Proiecte educationale si de formare medicala continua

IASP Grant: Musculoskeletal pain academy, 2011, IASP Developing Countries Project: Initiative for

improving pain education; jul2011-jul2012; (acord UMF “Gr.T.Popa” Iasi nr.12119/28.06.2011);

finantare IASP 7000 USD; (coordonator international)

IASP Grant IASP Developing Countries Project: Initiative For Improving Pain Education - Grant IASP

(International Association for the Study of Pain); Manager de proiect dr. Jaba Irina 05.2009-05.2010;

(accord UMF Iasi 8499/20.05.2009); finantare IASP 9700 USD, membru in echipa

Cursuri postuniversitare EMC acreditate, Facultatea Medicina, UMF Gr.T.Popa Iasi – Coordonator (6)

An universitar 2014/2015, http://www.umfiasi.ro/EMC/Documents/cursuri%20postuniversitare%202014-

2015/medicina%202014%202015.pdf

1. Sclerodermia sistematică (SS) – aspecte practice clinice şi terapeutice, 01.03-30.04.2015

An universitar 2010/2011 ( http://www.umfiasi.ro/EMC/EMC/EMC_Medicina_2010-2011.pdf)

2. Terapia biologica in boli inflamatorii cronice cu determinism imun, 1-31 mar 2011

3. Evaluare si monitorizare in bolile reumatismale inflamatorii cornice, 1-28 feb 2011

4. Sclerodermia sistemica (SS) – actualitati diagnostice si terapeutice, 1-30 apr 2011,

An universitar 2009/2010

5. Evaluare si monitorizare in bolile reumatismale inflamatorii cornice, 1-28 feb 2010

6. Sclerodermia sistemica (SS) – actualitati diagnostice si terapeutice, 1-30 apr 2010

Proiecte de educatie continua nationale (membru) (4)

PROIECT POSDRU 81/3.2/S/55648, Formare profesionala pentru implementarea noilor tehnologii

in sistemul de sanatate PERFORMED, director proiect – prof dr HD Bolosiu, UMF I Hatieganu Cluj-

Napoca, 2010-2013, competitie, fonduri 5.000.000 EURO, membru cu participare directa in realizarea si

prezentarea cursuri, Sesiunea de formare NE, http://performed.ro/;

http://performed.ro/simpozioane/sesiunea-de-formare-8-nord-est-iasi-10-13-septembrie-2013/

Master UMF Gr.T.Popa Iasi, specializarea Boli cu determinism imun, coordonator prof. univ dr Rodica

Marieta Chirieac (mai 2006-dec 2007); lector;

Tulburari de crestere staturo-ponderala, coordonator prof dr. Corina Galesanu; lector; (syllabus ISBN

978-973-7682-11-6), curs postuniverstar acreditat UMF Iasi, An universitar 2006/2007

Curriculum vitae | Codrina Irena Mihaela ANCUTA

15 | P a g e

Boli osoase endocrine-metabolice; coordonator prof dr C Galeasanu; lector

Lector cursuri postuniversitare formare continua (23)

1. Curs Osteoporoza (de la diagnostic la tratament) o provocare pentru practician, 28 feb-02 mar2013

Iasi, Romania, coordonator prof dr. Corina Galesanu; lector (Osteoporoza glucocorticoid indusa;

Osteoporoza la barbat)

2. Curs postuniversitar (Rolul medicului de familie in diagnosticarea, monitorizarea si managementul

poliartritei reumatoide, Lector, Conferinta Zilele Spitalului Clinic de Recuperare 3-7 apr 2012,

3. Conferinta Zilele Spitalului Clinic de Recuperare 3-7 apr 2012, Iasi, Romania; Manifestarile

cardiovasculare din bolile reumatismale imunoinflamatorii cronice: screening, diagnostic si management",

curs interdisciplinar Cardiologie-Reumatologie; lector (Hipertensiunea arteriala pulmonara in contextul

bolilor reumatismale: date epidemiologice, etiopatogenie, diagnostic clinic);

4. Curs EMC: Urgențe reumatologice în practica clinică, Conferinta ”Zilele Spitalului Clinic de Recuperare”

(editia a IX-a), 22-27 mar 2011, Iasi, Romania: Impactul recuperarii asupra calitatii vietii; lector (Criza

renala sclerodermica)

5. Curs postuniversitar: Dizabilitatea și calitatea vieții în bolile reumatismale cronice, Conferinta

“Zilele Spitalului Clinic de Recuperare” (editia a IX-a), 22-27 mar 2011, Iasi, Romania: Impactul recuperarii

asupra calitatii vietii. Lector (Poliartrita reumatoida, dizabilitatea si calitatea vietii)

6. Curs postuniversitar Reumatologie, 15-16 apr 2010, Iasi, Romania. Coordonator prof Chirieac R;

lector (Evaluarea – clinica, functionala, de calitate a vietii in poliartrita reumatoida; Posibile ratiuni clinice

pentru ciclizarea tratamentului anti-TNF; switching si efecte adverse)

7. Curs postuniversitar: Osteoporoza – boala cronica invalidanta. De la depistarea precoce la

tratament, 20 mar 2010, Iasi, Romania. Coordonator curs: prof Galesanu C, moderatori sesiune: prof

Galesanu C, prof Botez P; lector (Osteoporoza glucocorticoid indusa. Poliartrita reumatoida)

8. Curs postuniversitar: Osteoporoza – Aspecte teoretice si practice, Conferinta “Zilele Spitalului Clinic

de Recuperare” (editia a VII-a), 24-28 mar 2009, Iasi, Romania: Actualitati in preventia si recuperarea

medico-chirurgicala; coordonator prof dr. Rodica Chirieac; lector (Modalitati diagnostic in osteoporoza–

evaluarea DXA; Actualitati in managementul osteoporozei– medicatia antiosteoporotica cu actiune duala;

Actualitati in managementul osteoporozei – perspective terapeutice in osteoporoza; Monitorizarea terapeii

anti-osteoporotice

9. Curs postuniversitar: Performantele musculare si rolul in reeducarea functional din bolile

reumatismale, neurologice, cardio-vasculare, posttraumatice Conferinta “Zilele Spitalului Clinic de

Recuperare” (editia a VII-a), 24-28 mar 2009, Iasi, Romania: Actualitati in preventia si recuperarea medico-

chirurgicala; lector (Metode de reabilitare: metode electrice–stimularea electrica neuromusculara; Metode

de reabilitare: metode kinetoterapeutice – tehnici de facilitare; Particularitati ale muschiului si metode de

recuperare in boli reumatismale: poliartrita reumatoida, miopatii de tip inflamator, artroza)

10. Curs postuniversitar: Recuperarea medicala si reabilitarea – un act terapeutic de echipa;

coordonator: dr Gavrilas C. Manifestarea “Zilele Spitalului de Recuperare “Sf Gheorghe” Botosani”, 23-24

apr 2008, Botosani, Romania (editia I); Lector

Chirieac R, ANCUTA C, Tacu C, Gavrilas C, Recuperarea medicala si reabilitarea intre present si viitor, aspect ale

interdisciplinaritatii, Modul Recuperare; Rezus E, Chirieac R, ANCUTA C, Tacu C, Recuperarea soldului operat,

Modul Recuperare; ANCUTA C, Tacu C, Rezus E, Tehnici de facilitare in recuperare, Modul Recuperare; Rezus E,

Chirieac R, ANCUTA C, Tehnica exercitiului aerobic, modul Recuperare; Chirieac R, ANCUTA C, Gavrilas C, Evaluarea

clinica in poliartrita reumatoida si impactul pe reeducarea functionala, modul Reumatologie; ANCUTA C, Rezus E,

Gavrilas C, Evaluarea si monitorizarea tratamentului in bolile reumatismale inflamatorii cronice, modul

Reumatologie; Rezus E, Chirieac C, ANCUTA C, Evaluarea in osteoporoza, modul Reumatologie;Chirieac R, ANCUTA

C, Rezus E, Mecanismele durerii, modul Algeziologie; Rezus E, Chirieac R, ANCUTA C, Durerea din afectiunile

degenerative, modul Algeziologie; Ancuta Codrina, Chirieac R, Durerea de tip inflamator, modul Algeziologie

11. Curs postuniversitar: Bio-Care – terapie revolutionara in bolile autoimune: actualitati si

perspective (coordonator R. Chirieac), Conferinta “Zilele Spitalului Clinic de Recuperare Iasi, 20-22 mar

2008, Iasi, Romania; lector (Efecte adverse ale terapiei biologice. Infectia tuberculoasa – screening si

monitorizare; Terapia anti-CD20)

Curriculum vitae | Codrina Irena Mihaela ANCUTA

16 | P a g e

12. Curs postuniversitar: Actualitati in imunopatologia si terapia bolilor reumatismale cu determinism

imun, Conferinta “Zilele Spitalului Clinic de Recuperare Iasi” (editia a V-a), 29-31 mar 2007, Iasi, Romania;

lector

13. Curs postuniversitar: Exercitiu aerobic: implicatii teoretice si practice, Conferinta “Zilele Spitalului

Clinic de Recuperare Iasi” (editia a V-a), 29-31 mar 2007, Iasi, Romania; lector

14. Curs EMC: Managementul durerii in patologia reumatismala, 25 mai 2007, Iasi, Romania moderator

prof Chirieac R; Lector (Managementul durerii articulare in reumatismele inflamatorii

15. Curs EMC: 05 Dec 2007, Suceava, Romania; moderator prof Chirieac R; Lector, Terapii eficiente in

patologia musculoscheletala.

16. Curs postuniversitar: Terapia prin miscare. Aspecte fiziopatologice si practice, Conferinta “Zilele

Spitalului Clinic de Recuperare Iasi” (editia a IV-a), 6-8 apr 2006, Iasi, Romania;

R Chirieac, ANCUTA C, C Munteanu, Recuperarea aparatului musculo-scheletal; R Chirieac, L Macovei, I Boaru, C Tacu,

ANCUTA C, Parametrii fizici ai miscarii; R Chirieac, ANCUTA C, C Nacu, Metode practice de intretinere si recuperare a

miscarii: mobilitate, flexibilitate, ROM, posturari; ANCUTA C, C Tacu, Tehnici de facilitare

17. Curs EMC: Managementul bolii artrozice. Curs pentru depistarea, diagnosticarea precoce si

tratamentul bolii artrozice, 2006, Bacau, Romania. Lector, Terapia bolii artrozice si rolul coxibilor.

18. Curs EMC: Managementul bolii artrozice. Curs pentru depistarea, diagnosticarea precoce si

tratamentul bolii artrozice, 14 apr 2006 Suceava, Romania, lector, Boala artrozica – prezentare de caz

19. Curs EMC: Managementul bolii artrozice. Curs pentru depistarea, diagnosticarea precoce si

tratamentul bolii artrozice, 2006, Iasi, Romania, Lector, Boala artrozica – prezentare de caz

20. Curs EMC: Eficacitatea – obiectiv esential in tratamentul afectiunilor musculo-scheletale, 3 mar

2006, Iasi, Romania, coordonatori – prof dr. Chirieac R, ptof dr. Bolosiu H, lectori: Ionescu R, Balanescu A,

ANCUTA C, Rezus E, sarbu P

21. Curs EMC: Osteoporoza- o epidemie cu adevarat silentioasa?, 05 nov 2005, Iasi, Romania; moderator

Sirbu P, participant: Sirbu P, ANCUTA C (Fracturile vertebrale: cause declansatoare si preventia acestora),

Branisteanu D, Galesanu C (5 EMC)

22. Curs EMC: Patologia osteoarticulara la inceput de mileniu, 27 apr 2004, Iasi, Romania moderatori: prof

Chirieac R, Bolosiu H; ANCUTA C, Tratamentul biologic al afectiunilor cronice inflamatorii.

23. Curs EMC: Calitatea vietii virstnicului cu afectiuni musculo-scheletale, 26 nov 2003, Iasi, Romania,

moderator prof Chirieac R, lectori: prof Pandele G, conf Botez P, Rezus E, ANCUTA C (Caractere clinico-

patogenice, terapeutice si calitatea vietii varstnicului cu poliartrita reumatoida).

Membru in comitete științifice, organizator de manifestări științifice (18)

1. Organizator/coordonator Workshop – Poliartrita reumatoida – de la diagnostic la tratament – ANCUTA C,

Bojinca M, Ancuta I, Conferinta Zilele Spitalului Clinic de Recuperare Iasi, 25-29 mar 2014, Iasi, Romania,

2. Organizator/ coordonator Workshop, Artropatiile microcristaline: o noua abordare patogenica, diagnostica

si terapeutica, Conferinta Zilele Spitalului Clinic de Recuperare Iasi, 25-29 mar 2013, Iasi, Romania

3. Comitet de organizare Conferinta Zilele Spitalului Clinic de Recuperare Iasi, 26-29 mar 2013, Iasi, Romania

4. Comitet de organizare/ Coordonator modul Reumatologie II: Autoimunitatea la pacientul varstnic:

particularitati de diagnostic si terapie; Conferinta Zilele Spitalului Clinic de Recuperare Iasi – editia XI, 26-29

mar 2013, Iasi, Romania

5. Comitet de organizare Conferinta Zilele Spitalului Clinic de Recuperare Iasi, 3-7apr 2012, Iasi, Romania

6. Congresul Roman de Reumatologie 23-26 nov 2011; Brasov, Romania

7. Comitet de organizare Congresul Roman de Reumatologie, 19-22 oct 2010, Brasov, Romania

8. Comitet de organizare Conferinta Zilele Spitalului Clinic de Recuperare Iasi (editia a VIII-a), 23-27 mar 2010,

Iasi, Romania

9. Comitet de organizare Conferinta Zilele Spitalului Clinic de Recuperare Iasi (editia a VII-a), 24-28 mar 2009,

Iasi, Romania

10. Comitet de organizare Coferinta Zilele Spitalului Clinic de Recuperare Iasi, Editie aniversara 30 ani, 20-22

martie 2008

11. Congresul National de Reumatologie cu participare internationala, 14-17 sep 2005, Brasov, Romania

Curriculum vitae | Codrina Irena Mihaela ANCUTA

17 | P a g e

12. Conferinta Zilele Spitalului Recuperare 27-29 mar 2003, Iasi, Romania

13. Conferinta Nationala de reumatologie cu participare internationala, Iasi, 28-30 mai 1998

14. Consiliul stiintific al XXI-lea Congres National de Reumatiologie, 1-4 Oct 2014, Bucuresti

15. Comitet stiintific Conferinta Zilele Spitalului Clinic de Recuperare Iasi editia a XII-a, 25-29 Martie 2014,

Iasi, Romania

16. Comitet stiintific al XX-lea Congres National de Reumatologie 25-28 sept 2013, Bucuresti,

17. Comitet stiintific – Zilele Spitalului de Recuperare Sf Gheorghe Botosani, editia 1, 23-24 apr 2008, Botosani,

Romania

18. Secretar stiintific Congresul National OSART, 14-17 mai 2008, Iasi, Romania

Brevete de inventie: 2 internationale (vezi lista completa de lucrari anexata)

Evaluare activitate didactica si cercetare anuala – in primele 10 locuri din universitate in ultimii 3 ani (http://www.umfiasi.ro/Pages/Default.aspx)

Nume si adrese contact personalitati din domeniu pentru recomandare

Professor Ariane HERRICK, professor of Rheumatology, University of Msnchester, UK, Telephone +44

(0)161 275 5993; Email: ariane.herrick@manchester.ac.uk (recomandare atasata)

Prof univ dr. Mioara BANCIU, Email: maiabanciu@yahoo.com, mobil 0744925789Timisoara, Romania

(recomandare atasata)

Prof univ dr. Maria SUTA, Email: mariasuta@yahoo.com; mobil: 0723213019, Constanta, Romania

(recomandare atasata)

Conf univ dr. Denisa PRESETEANU, Email: dpredet@yahoo.com; mobil 0723640548, Bucuresti, Romania

(recomandare atasata)

Prof univ dr Laurentiu MOGOANTA, Email: laurentiu_mogoanta@yahoo.com, Craiova, Romania,

(recomandare atasata)

Prof univ Eugen CARASEVICI, Iasi, Romania, Email: eugen.carasevici@gmail.com

Prof univ dr Minodora MAZUR, Chisinau, Moldova, email: mminodora2001@yahoo.com

Prof univ dr Liliana GROPPA, Chisinau, Moldova, email: lgroppa@gmail.com

Curriculum vitae | Codrina Irena Mihaela ANCUTA

18 | P a g e

Recunoasterea contributiilor stiintifice: (272 citari) (254 citari in reviste cotate ISI)

Adresa web pt citari: http://scholar.google.ro/scholar?start=50&q=codrina+ancuta&hl=ro&as_sdt=0,5

http://scholar.google.ro/scholar?q=ancuta+c&btnG=&hl=ro&as_sdt=0%2C5

Articol citat: A phase II, randomized, double‐blind, placebo‐controlled study evaluating the efficacy and safety

of MDX‐1100, a fully human anti‐CXCL10 monoclonal …, …, H LeBlanc, G Nichol, C Ancuta… - Arthritis & …,

2012 - Wiley Online Library

1. B cells as therapeutic targets in SLE, I Sanz et al, Nature Reviews Rheumatology, 2010 - nature.com,

2. Chemokines: established and novel targets in atherosclerosis, RR Koenen et al, EMBO molecular medicine,

2011 - embomolmed.embopress.org

3. Innovative therapies for systemic sclerosis, VH Ong, CP Denton, Current opinion in rheumatology, 2010 -

journals.lww.com

4. Trial Watch, L Zitvogel, G Kroemer - 2012 - landesbioscience.com, [HTML] from nih.gov (CITARE BDI)

5. CXCL10 and its receptor CXCR3 regulate synovial fibroblast invasion in rheumatoid arthritis, T Laragione et

al, Arthritis & …, 2011 - Wiley Online Library

6. Synoviocyte innate immune responses: TANK-binding kinase-1 as a potential therapeutic target in

rheumatoid arthritis, D Hammaker et al, Rheumatology, 2012

7. B cell therapies for rheumatoid arthritis: beyond B cell depletion, I Calero et al, Rheumatic Disease Clinics of

North America, 2010 – Elsevier

8. International Union of Basic and Clinical Pharmacology. LXXXIX. Update on the Extended Family of

Chemokine Receptors and Introducing a New Nomenclature for …, F Bachelerie et al, Pharmacological …,

2014 – ASPET,

9. Rheumatoid arthritis therapy: advances from bench to bedside, SI Choi, E Brahn, Autoimmunity, 2010

10. Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study, L Mayer et al, Gut,

2014

11. Enhanced expression of CXCL10 in inflammatory bowel disease: Potential role of mucosal toll‐like receptor 3

stimulation, AE Østvik et al, Inflammatory bowel …, 2012 - Wiley Online Library

12. Chemokine (C–X–C motif) ligand (CXCL) 10 in autoimmune diseases, A Antonelli et al, Autoimmunity …, 2014

– Elsevier

13. The interaction between CXCL10 and cytokines in chronic inflammatory arthritis, EY Lee, ZH Lee, YW Song -

Autoimmunity reviews, 2013 – Elsevier

14. Targeting chemokines and chemokine receptors with antibodies, A Klarenbeek et al, Drug Discovery Today:

…, 2013 – Elsevier

15. Liver X receptor regulates rheumatoid arthritis fibroblast-like synoviocyte invasiveness, matrix

metalloproteinase 2 activation, interleukin-6 and CXCL10, T Laragione, PS Gulko, Molecular Medicine, 2012

16. Monoclonal antibody against CXCL-10/IP-10 ameliorates influenza A (H1N1) virus induced acute lung injury,

W Wang et al, Cell …, 2013 - ncbi.nlm.nih.gov, [HTML] from nature.com

17. Safety and Efficacy of the Newer Biological Therapeutics in the Treatment of Rheumatoid Arthritis, V

Navarro-Compán… - Clinical Medicine Insights …, 2011

18. Emerging therapies for rheumatoid arthritis, P Jacques, F Van den Bosch, Expert opinion on emerging …,

2013

19. Prolonged TNFα primes fibroblast‐like synoviocytes in a gene‐specific manner by altering chromatin, C Sohn

et al, Arthritis & …, 2014 - Wiley Online Library

20. Review: new anti-cytokines for IBD: what is in the pipeline?, M Scharl, SR Vavricka, G Rogler, Current drug

targets, 2013 - ingentaconnect.com

21. The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis, DL Boyle et al,

Annals of the …, 2014 - ard.bmj.com

22. Перспективы фармакотерапии ревматоидного артрита: моноклональные антитела, ЕЛ Насонов, ЛН

Денисов… - Научно-практическая …, 2012 - cyberleninka.ru

23. Thymidine Phosphorylase Regulates the Expression of CXCL10 in Rheumatoid Arthritis Fibroblast‐like

Synoviocytes, Y Toyoda et al, Arthritis & …, 2014 - Wiley Online Library

24. Chemokines and chemokine receptors blockers as new drugs for the treatment of chronic obstructive

pulmonary disease, G Caramori et al, Current medicinal …, 2013 - ingentaconnect.com

25. Brief Report: Inadequate Description and Discussion of Enrolled Patient Characteristics and Potential Inter–

Study Site Differences in Reports of Randomized …, S Yurdakul et al, Arthritis & …, 2014 - Wiley Online

Library

Curriculum vitae | Codrina Irena Mihaela ANCUTA

19 | P a g e

26. Targeting Chemokine (CXC motif) Receptor 3 in Thyroid Autoimmunity, P Fallahi et al, Recent patents on …,

2014 - ingentaconnect.com

27. Inflammatory cytokines epigenetically regulate rheumatoid arthritis fibroblast-like synoviocyte activation by

suppressing HDAC5 expression, C Angiolilli et al, Annals of the …, 2014 - ard.bmj.com

28. Novel treatment options for ulcerative colitis, BP Vaughn, AC Moss - Clinical investigation, 2013 - Future

Science

29. Anti-inflammatory drimane sesquiterpene lactones from an< i> Aspergillus</i> species, S Felix et al,

Bioorganic & medicinal chemistry, 2014 – Elsevier

30. World Journal of Pharmaceutical ReseaRch, K Sekhri, R Nandha, S Aditya - 2014 - wjpr.net

31. The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis, DL Boyle et al,

Annals of the …, 2014 - ard.bmj.com

32. Перспективы фармакотерапии ревматоидного артрита: моноклональные антитела, ЕЛ Насонов, ЛН

Денисов… - Научно-практическая …, 2012 - cyberleninka.ru

33. Thymidine Phosphorylase Regulates the Expression of CXCL10 in Rheumatoid Arthritis Fibroblast‐like

Synoviocytes, Y Toyoda et al, Arthritis & …, 2014 - Wiley Online Library

34. Chemokines and chemokine receptors blockers as new drugs for the treatment of chronic obstructive

pulmonary disease, G Caramori, A Di Stefano, P Casolari… - Current medicinal …, 2013 - ingentaconnect.com

35. Brief Report: Inadequate Description and Discussion of Enrolled Patient Characteristics and Potential Inter–

Study Site Differences in Reports of Randomized …, S Yurdakul, BN Mustafa, I Fresko… - Arthritis & …, 2014 -

Wiley Online Library

36. Targeting Chemokine (CXC motif) Receptor 3 in Thyroid Autoimmunity, P Fallahi, S Martina Ferrari, A

Corrado… - Recent patents on …, 2014 - ingentaconnect.com

37. Inflammatory cytokines epigenetically regulate rheumatoid arthritis fibroblast-like synoviocyte activation by

suppressing HDAC5 expression, C Angiolilli, AM Grabiec, BS Ferguson… - Annals of the …, 2014 -

ard.bmj.com

38. Current and prospective pharmacotherapy for autoimmune hepatitis, AJ Czaja - Expert opinion on

pharmacotherapy, 2014 - informahealthcare.com

39. The Role of CXCR3 in DSS-Induced Colitis, B Chami, AWS Yeung, C van Vreden, NJC King, S Bao - PloS one,

2014 - dx.plos.org

40. Role of CXCL10 in central nervous system inflammation, D Michlmayr, CS McKimmie - International Journal

of Interferon, …, 2014 - dovepress.com

41. Therapeutic effect of anti-CXC motif chemokine 10 (CXCL10) antibody on C protein-induced myositis mouse, J

Kim, JY Choi, SH Park, SH Yang… - Arthritis research & …, 2014 - biomedcentral.com

42. CXCR3 ligands in disease and therapy, K Van Raemdonck, PE Van den Steen… - Cytokine & Growth …, 2014 –

Elsevier

43. Review article: chemokines as orchestrators of autoimmune hepatitis and potential therapeutic targets, AJ

Czaja - Alimentary Pharmacology & Therapeutics, 2014 - Wiley Online Library

44. Chemokine receptors as important regulators of pathogenesis during arboviral encephalitis, D Michlmayr, JK

Lim - Frontiers in cellular neuroscience, 2014 - ncbi.nlm.nih.gov

45. MAbs Targeting Soluble Mediators in Phase 1 and 2 Clinical Studies Immunological Disorders, FR Brennan -

Handbook of Therapeutic Antibodies - Wiley Online Library

46. Chemokines and chemokine receptors: Update on utility and challenges for the clinician, I Roy, DB Evans, MB

Dwinell - Surgery, 2014 - surgjournal.com

47. G protein-coupled receptors in rheumatology, E Neumann, K Khawaja, U Müller-Ladner - Nature Reviews …,

2014 - nature.com

48. CXCL10, TNFR2 and Galectin‐9 correlate with disease activity in Juvenile Dermatomyositis, F Bellutti Enders,

F van Wijk, R Scholman… - Arthritis & …, 2014 - Wiley Online Library

49. Th1-like Innate Lymphoid Cells Accumulate in the Intestinal Lesions of Patients with Crohn's Disease, JOM List

- Immunity, 2013 - focisnet.org

50. BET bromodomain inhibition suppresses transcriptional responses to cytokine‐Jak‐STAT signaling in a gene‐

specific manner in human monocytes, CH Chan, C Fang, Y Qiao, A Yarilina… - European journal of …, 2014 -

Wiley Online Library

51. The multiple chemokine-binding Bovine Herpesvirus 1 Glycoprotein G (BHV1gG) inhibits polymorphonuclear

cell but not monocyte migration into inflammatory …. Z Liu, R Bethunaickan, R Sahu, M Brenner… -

Molecular medicine …, 2013 - researchgate.net

Curriculum vitae | Codrina Irena Mihaela ANCUTA

20 | P a g e

52. Investigative Approaches to Drug Therapy, VH Ong, CP Denton - Scleroderma, 2012 – Springer

53. Динамика уровней цитокинов на фоне терапии метотрексатом и адалимумабом у пациентов с

ранним ревматоидным артритом (исследование РЕМАРКА), AЕ Каратеев, AЛ Лучихина… - Научно-

практическая …, 2014 - rsp.ima-press.net

54. Целесообразность и перспективы применения антицитокиновой и иммунокорригирующей

терапии у пациентов с хронической обструктивной болезнью …, AД Таганович - Пульмонология,

2014 - journal.pulmonology.ru

55. Rheumatoid arthritis and bacterial infections, NL Prokopjeva, NN Vesikova, IM Marusenko… - … Science and

Practice, 2008 - rsp-j.ru

56. Untersuchungen zur Funktion enterischer Gliazellen bei der Vermittlung der angeborenen Immunantwortș FI

Intensivmedizin - 2014 - qucosa.de (CITARE BDI)

ARTICOL CITAT: Determinants of discordance in patients' and physicians' rating of rheumatoid arthritis

disease activity, …, E Abda, A Aggarwal, R Alten, C Ancuta… - Arthritis care & …, 2012 - Wiley Online Library

1. Discrepancies between patients and physicians in their perceptions of rheumatoid arthritis disease activity, P

Studenic, H Radner, JS Smolen… - Arthritis & …, 2012 - Wiley Online Library

2. Effect and treatment of chronic pain in inflammatory arthritis, YC Lee - Current rheumatology reports, 2013

– Springer

3. Validity and reliability problems with patient global as a component of the ACR/EULAR remission criteria as

used in clinical practice, KR Masri, TS Shaver, SH Shahouri, S Wang… - The Journal of …, 2012 - jrheum.org

4. Near misses of ACR/EULAR criteria for remission: effects of patient global assessment in Boolean and index-

based definitions, P Studenic, JS Smolen, D Aletaha - Annals of the rheumatic diseases, 2012 - ard.bmj.com

5. The importance of patient participation in measuring rheumatoid arthritis flares, CO Bingham, R Alten, MP

de Wit - Annals of the rheumatic diseases, 2012 - ard.bmj.com

6. Characterization of rheumatoid arthritis subtypes using symptom profiles, clinical chemistry and

metabolomics measurements, HA van Wietmarschen, W Dai, AJ van der Kooij… - PloS one, 2012 - dx.plos.org

7. Patient's global assessment of disease activity: what are we measuring?, LHD van Tuyl, M Boers - Arthritis &

Rheumatism, 2012 - Wiley Online Library,

8. Adherence to a treat-to-target strategy in early rheumatoid arthritis: results of the DREAM remission

induction cohort, M Vermeer, HH Kuper, HJB Moens… - Arthritis research & …, 2012 - biomedcentral.com

9. Patients' views about treatment with combination therapy for Rheumatoid Arthritis: a comparative

qualitative study, H Lempp, D Hofmann, SL Hatch… - BMC musculoskeletal …, 2012 - biomedcentral.com

10. Impact of socioeconomic gradients within and between countries on health of patients with rheumatoid

arthritis (RA): Lessons from QUEST RA, P Putrik, T Sokka, S Ramiro, A Boonen - Best Practice & Research

Clinical …, 2012 – Elsevier

11. Long-term sustained remission in a cohort study of patients with rheumatoid arthritis: choice of remission

criteria, B Svensson, MLE Andersson, SV Bala, K Forslind… - BMJ open, 2013 - bmjopen.bmj.com

12. Establishing a core domain set to measure rheumatoid arthritis flares: report of the OMERACT 11 RA Flare

Workshop, VP Bykerk, E Lie, SJ Bartlett, R Alten… - The Journal of …, 2014 - jrheum.org

13. Comparison of physician and patient global assessments over time in patients with rheumatoid arthritis: a

retrospective analysis from the RADIUS cohort, JA Markenson, AS Koenig, JY Feng… - JCR: Journal of …, 2013

- journals.lww.com

14. Understanding how patients (vs physicians) approach the decision to escalate treatment: a proposed

conceptual model, L Fraenkel, EK Seng, M Cunningham… - …, 2014 - Br Soc Rheumatology

15. Further optimization of the reliability of the 28-joint Disease Activity Score in patients with early rheumatoid

arthritis, L Siemons, M Peter, HE Vonkeman, MAFJ van de Laar… - PloS one, 2014 - dx.plos.org

16. Discordance of Global Estimates by Patients and Their Physicians in Usual Care of Many Rheumatic Diseases:

Association With 5 Scores on a Multidimensional …, I Castrejón, Y Yazici, J Samuels, G Luta… - Arthritis care

& …, 2014 - Wiley Online Library

17. The Role of Depression, Anxiety, Fatigue, and Fibromyalgia on the Evaluation of the Remission Status in

Patients with Rheumatoid Arthritis, N Inanc, S Yilmaz-Oner, M Can, T Sokka… - The Journal of …, 2014 -

jrheum.org

18. Vectra DA for the objective measurement of disease activity in patients with rheumatoid arthritis, OG

Segurado, EH Sasso - Clinical and experimental …, 2014 - clinexprheumatol.org, ABSTRACT

19. Predictors of Outcome Following Standardized Rehabilitation for Patients with Shoulder Pain, SD Moore -

2013 - uknowledge.uky.edu

Curriculum vitae | Codrina Irena Mihaela ANCUTA

21 | P a g e

20. Pain in rheumatoid arthritis: a critical review, P Sarzi-Puttini, F Salaffi, M Di Franco, L Bazzichi… -

Reusmatismo, 2014 - reumatismo.org

21. Assessment of global disease activity in RA patients monitored in the METEOR database: the patient's versus

the rheumatologist's opinion, E Gvozdenović, R Koevoets, R Wolterbeek… - Clinical …, 2014 – Springer

22. Health Literacy Predicts Discrepancies Between Traditional Written Patient Assessments and Verbally

Administered Assessments in Rheumatoid Arthritis, JM Hirsh, LA Davis, I Quinzanos, A Keniston… - The

Journal of …, 2014 - jrheum.org

23. Discordance in Global Assessments Between Patient and Estimator in Patients with Newly Diagnosed

Rheumatoid Arthritis: Associations with Progressive Joint …, Y Kaneko, M Kuwana, H Kondo… - The Journal

of …, 2014 - jrheum.org

24. " Stiffness has different meanings, I think, to everyone". examining stiffness from the perspective of people

living with rheumatoid arthritis, AM Orbai, KC Smith, SJ Bartlett… - Arthritis Care & …, 2014 - Wiley Online

Library

25. Individual patient monitoring in daily clinical practice: a critical evaluation of minimal important change, aJ

Hendrikx, J Fransen, W Kievit, PLCM van Riel - Quality of Life Research, 2014 – Springer,

26. Factors explaining the discrepancy between physician and patient global assessment of joint and skin disease

activity in psoriatic arthritis patients, L Eder, A Thavaneswaran, V Chandran… - Arthritis care & …, 2014 -

Wiley Online Library

27. Benefits and risks of targeted treatment in rheumatoid arthritis, L Dirven - 2012 - dspace.ubvu.vu.nl

(CITARE BDI)

28. A systems approach to sub-typing of rheumatoid arthritis, HA Wietmarschen - 2012 -

openaccess.leidenuniv.nl (CITARE BDI)

Articol citat: Comparison of two referral strategies for diagnosis of axial spondyloarthritis: the Recognising

and Diagnosing Ankylosing Spondylitis Reliably (RADAR) study, …, D Danda, T Reitblat, F Cantini, C Ancuta…

- Annals of the …, 2012 - ard.bmj.com

1. Optimizing the identification of patients with axial spondyloarthritis in primary care—the case for a two-step

strategy combining the most relevant clinical items …, A Braun, H Gnann, E Saracbasi, J Grifka… - …, 2013 -

Br Soc Rheumatology

2. Recomendations for the Detection, Study and Referral of Inflammatory Low-back Pain in Primary Care, XJ

Roura, EC Estévez, FL Vázquez, AT Villamor… - … Clínica (English Edition), 2014 – Elsevier

3. Advances in classification, basic mechanisms and clinical science in ankylosing spondylitis and axial

spondyloarthritis, PC Robinson, H Benham - Internal medicine journal, 2014 - Wiley Online Library;

4. Nonradiographic axial spondyloarthritis background and confounding factors of this new terminology: an

appraisal, J Erbil, LR Espinoza - Clinical rheumatology, 2014 – Springer

5. Spondyloarthritis: recognition, imaging, treatment, R Berg - 2014 - openaccess.leidenuniv.nl

6. Consensus statement on the investigation and management of non‐radiographic axial spondyloarthritis (nr‐

axSpA), PC Robinson, P Bird, I Lim, N Saad… - … journal of rheumatic …, 2014 - Wiley Online Library

7. Men's Experiences of Living with Ankylosing Spondylitis: A Qualitative Study, M Madsen, KV Jensen, BA

Esbensen - Musculoskeletal care, 2014 - Wiley Online Library

8. Referral strategy for early recognition of axial spondyloarthritis: consensus recommendations from the Hong

Kong Society of Rheumatology, CC Mok, LS Tam, MH Leung, KY Ying… - … journal of rheumatic …, 2013 -

Wiley Online Library

9. Similarities and differences between nonradiographic and radiographic axial spondyloarthritis: a clinical,

epidemiological and therapeutic assessment, D Poddubnyy, J Sieper - Current opinion in rheumatology,

2014 - journals.lww.com

10. General Practitioners' Perceptions of Their Ability to Identify and Refer Patients with Suspected Axial

Spondyloarthritis: A Qualitative Study, M van Onna, S Gorter, A van Meerendonk… - The Journal of …, 2014 -

jrheum.org

11. Recognition of Preclinical and Early Disease in Axial Spondyloarthritis, D Wallis, RD Inman - Rheumatic

Disease Clinics of North America, 2014 – Elsevier

12. The burden of Non-radiographic Axial Spondyloarthritis, A Boonen, J Sieper, D van der Heijde… - Seminars

in Arthritis and …, 2014 – Elsevier

13. Classification and Diagnosis of Axial Spondyloarthritis—What Is the Clinically Relevant Difference?, J Braun,

X Baraliakos, U Kiltz, F Heldmann… - The Journal of …, 2014 - jrheum.org

14. The prevalence of inflammatory back pain in a UK primary care population, L Hamilton, A Macgregor, V

Warmington… - …, 2014 - Br Soc Rheumatology

Curriculum vitae | Codrina Irena Mihaela ANCUTA

22 | P a g e

15. Comparación de 2 estrategias de derivación en el diagnóstico de la espondiloartritis axial en España. Estudio

RADAR, XJ Roura, JLF Sueiro, JCT Alonso… - Reumatología …, 2013 - dialnet.unirioja.es

16. Recomendaciones para la detección, investigación y derivación del dolor lumbar inflamatorio en Atención

Primaria, XJ Roura, EC Estévez, FL Vázquez, AT Villamor… - Reumatología …, 2014 – Elsevier

Articol citat: Patient's global assessment of disease activity and patient's assessment of general health for

rheumatoid arthritis activity assessment: are they equivalent?, …, EA Abda, R Alten, C Pohl, C Ancuta… - Annals

of the …, 2012 - ard.bmj.com;

1. Near misses of ACR/EULAR criteria for remission: effects of patient global assessment in Boolean and index-

based definitions, P Studenic, JS Smolen, D Aletaha - Annals of the rheumatic diseases, 2012 - ard.bmj.com

2. Impact of socioeconomic gradients within and between countries on health of patients with rheumatoid

arthritis (RA): Lessons from QUEST RA, P Putrik, T Sokka, S Ramiro, A Boonen - Best Practice & Research

Clinical …, 2012 – Elsevier

3. Discordance of Global Estimates by Patients and Their Physicians in Usual Care of Many Rheumatic Diseases:

Association With 5 Scores on a Multidimensional …, I Castrejón, Y Yazici, J Samuels, G Luta… - Arthritis care

& …, 2014 - Wiley Online Library

4. The Role of Depression, Anxiety, Fatigue, and Fibromyalgia on the Evaluation of the Remission Status in

Patients with Rheumatoid Arthritis, N Inanc, S Yilmaz-Oner, M Can, T Sokka… - The Journal of …, 2014 -

jrheum.org

5. Rheumatoid Arthritis in the Elderly in the Era of Tight Control, M Soubrier, Z Tatar, M Couderc, S Mathieu, JJ

Dubost - Drugs & aging, 2013 – Springer

6. Aiming for SDAI remission versus low disease activity at 1 year after inclusion in ESPOIR cohort is associated

with better 3-year structural outcomes, A Ruyssen-Witrand, G Guernec, D Nigon… - Annals of the …, 2014 -

ard.bmj.com

7. Patients with rheumatoid arthritis have better functional and working ability but poorer general health and

higher comorbidity rates today than in the late 1990s, T Uutela, H Kautiainen, S Järvenpää… - Scandinavian

…, 2014 - informahealthcare.com

8. Clinical measurement of disease activity in rheumatoid arthritis: why, how and utility of patient self-

assessment, PP Cheung, L Gossec - International Journal of Clinical …, 2014 - Future Medicine

9. Health Literacy Predicts Discrepancies Between Traditional Written Patient Assessments and Verbally

Administered Assessments in Rheumatoid Arthritis, JM Hirsh, LA Davis, I Quinzanos, A Keniston… - The

Journal of …, 2014 - jrheum.org

10. Patient‐Reported Improvement in Rheumatoid Arthritis is Associated With Different Measures of Arthritis

Activity When Assessed Prospectively Versus Retrospectively …, MM Ward, LC Guthrie, MI Alba - Arthritis

care & research, 2014 - Wiley Online Library

11. Growing up with Juvenile Idiopathic Arthritis, A McKeever, MM Kelly - MCN: The American Journal of

Maternal/ …, 2015 - journals.lww.com

Articol citat: Carotid intima-media thickness and plaque as surrogate biomarkers of atherosclerosis among

consecutive women with systemic lupus erythematosus, C Belibou, C Ancuţa, E Ancuţa, C Filoş… - Rom J

Morphol Embryol, 2012 - rjme.ro

1. Study of anti-apolipoprotein AI antibodies and paraoxonase 1 activity in systemic lupus erythematosus

patients; correlation with disease activity and damage …, EM Elserougy, II El-Gazzar, MM Ahmed… - The

Egyptian …, 2013 – Elsevier

2. ROLE OF ANTI PHOSPHORYLCHOLINE (ANTI-PC) ANTIBODIES IN CARDIOVASCULAR AFFECTION OF

SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS, NMGHA Selima, AM Gaballahb, SS Khalilc -

zumedicaljournal.com (CITARE BDI)

3. Anti-apolipoprotein A-1 antibodies and carotid intima–media thickness in Egyptian women with systemic

lupus erythematosus, MM Radwan, D El-Lebedy, R Fouda, E Elsorougy… - Clinical …, 2014 – Springer

4. Subclinical atherosclerosis in systemic lupus erythematosus patients and its relationship to disease activity

and damage indices, S Fadda, H Nassar, SM Gamal, H Al-Azizi - Zeitschrift für Rheumatologie, 2014 –

Springer

5. Hyperhomocysteinemia and metabolic syndrome are risk factors for sub-clinical atherosclerosis in women

with systemic lupus erythematosus, E Baraka, M El Dein, H Farouk, Y El Moutaz - The Egyptian

Rheumatologist, 2014 – Elsevier

Curriculum vitae | Codrina Irena Mihaela ANCUTA

23 | P a g e

6. ASSOCIATION OF CAROTID INTIMA-MEDIA THICKNESS WITH LEPTIN AND APOLIPOPROTEIN

B/APOLIPOPROTEIN AI RATIO REVEALS IMMINENT …, K Asha, A Singal, SB Sharma, A Aggarwal -

orbis.lfhk.cuni.cz (CITARE BDI)

7. Intima media thickness measurement as a marker of subclinical atherosclerosis in SLE patient, A Smrzova, P

Horak, M Skacelova… - Biomedical …, 2013 - biomed.papers.upol.cz 8. 药物治疗对系统性红斑狼疮患者血脂的影响, 吴鹰，王剑华，马海智，崔敏 - 广东医学, 2013 - cqvip.com

Articol citat: Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis

using the EUSTAR database, …, A Dumitrascu, I Tiglea, R Chirieac, C Ancuta… - Annals of the …, 2014 -

ard.bmj.com

1. Observational Cohort Studies in Rheumatic Diseases, SK Cho, D Kim, YK Sung - Korean Journal of Medicine,

2014 - synapse.koreamed.org

2. Systemic Sclerosis: Results from a multicenter survey of Norwegian patients, AM Hoffmann-Vold - 2014 -

duo.uio.no

3. Esclerosis sistémica. Evaluación clínico-epidemiológica de una serie de casos en dos centros de referencia en

Cuba, GAR Llerena, ZMG Toledano… - Revista Cubana de …, 2014 - revreumatologia.sld.cu 4. 류마티스질환의코호트연구, SK Cho, D Kim, YK Sung - 대한내과학회지, 2014 - ekjm.org

5. Factors Influencing Delay in Symptom-to-Door Time in Patients with Acute ST-Segment Elevation Myocardial

Infarction, JH Lee, MH Jeong, J Rhee, JS Choi… - Korean Journal of …, 2014 - synapse.koreamed.org

Articol citat Adalimumab therapy in patients with active rheumatoid arthritis., C Ancuţa, E Ancuţa, S Miu,

C Iordache… - … medico-chirurgicala a …, 2008 - europepmc.org

1. Activation of Sirt1 by resveratrol inhibits TNF-α induced inflammation in fibroblasts, X Zhu, Q Liu, M Wang, M

Liang, X Yang, X Xu, H Zou… - PloS one, 2011 - dx.plos.org

2. Retrospective cohort study of anti-tumor necrosis factor agent use in a veteran population, M Bounthavong,

N Madkour, R Kazerooni - PeerJ, 2014 - peerj.com

3. Untersuchungen zum Krankheitsverlauf von Patienten mit Morbus Crohn unter der Therapie mit

Adalimumab, C Reichel - rosdok.uni-rostock.de (CITARE BDI)

Articol citat: Effects of Pilates, McKenzie and Heckscher training on disease activity, spinal motility and

pulmonary function in patients with ankylosing spondylitis: a randomized …, MO Roşu, I Ţopa, R

Chirieac, C Ancuta - Rheumatology international, 2014 – Springer

1. Effects of physical therapy for the management of patients with ankylosing spondylitis in the biological era, E

Giannotti, S Trainito, G Arioli, V Rucco… - Clinical rheumatology, 2014 – Springer

2. Exercise therapy for spondyloarthritis: a systematic review, T O'Dwyer, F O'Shea, F Wilson - Rheumatology

international, 2014 – Springer

3. Exercise as an anti-inflammatory therapy for rheumatic diseases [mdash] myokine regulation, FB Benatti, BK

Pedersen - Nature Reviews Rheumatology, 2014 - nature.com

4. Nonpharmacologic therapies in spondyloarthritis, AM Reimold, V Chandran - Best Practice & Research

Clinical …, 2014 – Elsevier

5. [DOC] “COMPARATIVE EFFECT OF PILATES WITH MCKENZIE VERSUS CALLISTHENICS WITH MCKENZIE

PROGRAM FOR HOCKEY PLAYERS WITH …, MO Rosu - rguhs.ac.in (CITARE BDI)

Articol citat: [Prospective study of the efficiency and safety of adalimumab in treatment of active established

rheumatoid arthritis].; C Pomirleanu, C Ancuţa, L Macovei… - … medico-chirurgicala a …, 2011 - europepmc.org 1. 治疗性单克隆抗体药物的现状及发展趋势, 王志明，高健，李耿 - 中国生物工程杂志, 2013 -

159.226.100.150 (CITARE BDI)类风湿关节炎治疗药物的研究进展, 兰芬，阳凌燕，管剑龙 - 药学服务与研

究, 2013 - 万方数据资源系统(CITARE BDI)

Articol citat: [Clinico-biological issues of systemic lupus erythematosus patients].; IC Belibou, C Ancuţa,

S Miu, E Ancuţa… - … medico-chirurgicala a …, 2011 - europepmc.org

1. Long-term cardiac changes in patients with systemic lupus erythematosus, MF de Godoy, CM de Oliveira,

VA Fabri… - BMC research …, 2013 - biomedcentral.com

Curriculum vitae | Codrina Irena Mihaela ANCUTA

24 | P a g e

Articol citat: Importance of posture assessment in ankylosing spondylitis. Preliminary study, MO Roşu, C

Ancuţa, C Iordache… - … medico-chirurgicala a …, 2012 - revmedchir.ro

1. Postural Control and Balance in Ankylosing Spondylitis, T Yildirim, O Yildirim - Medicine Science| International

Medical Journal - ejmanager.com

2. Evidencia científica de la rehabilitación en la espondilitis anquilosante, A Bigorda-Sague, MA Castellano-del-

Castillo… - Rehabilitación, 2014 – Elsevier

Articol citat: Immunohistochemical study of skeletal muscle in rheumatoid myositis, C Ancuţa, E Ancuţa, C

Iordache… - Romanian Journal of …, 2009 - researchgate.net

1. Anti-inflammatory effect of plant compositions of Tibetan medicine in vitro on early rheumatoid arthritis, LY

Semenova, JM Salmasi, GV Poryadin - Health, 2011 - file.scirp.org

Articol citat: [Identification of bone mass and bone turnover in patients with rheumatoid arthritis treated with

corticosteroids in order to elaborate an optimal therapeutic approach]., L Macovei, C Ancuţa, C Pomîrleanu… -

… medico-chirurgicala a …, 2011 - europepmc.org;

1. 男性类风湿关节炎患者骨质疏松与骨密度的临床研究, 马喜喜，刘童，徐胜前，沈晓濛，胡琳玮… - 中华临

床医师杂志( …, 2013 - clinicmed.net (citare BDI)

Alendronate for postmenopausal osteoporosis: focus on bone resorption biomarker, E Ancuta, C Ancuta, C

Iordache… - …, 2010 - … LONDON LTD 236 GRAYS INN RD, …

1. Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment:

the secondary prevention of fractures, and primary …, J Burch, S Rice, H Yang, A Neilson, L Stirk… - Health

technology …, 2014 - sefap.org

[CITATION] Changes in bone mineral density during anti-TNF alpha therapy in rheumatoid arthritis patients,

C Ancuta, R Chiriac, E Ancuta… - …, 2007 - SPRINGER LONDON LTD …

1. Gateways to clinical trials, M Bayes, X Rabasseda, JR Prous - Methods and findings in …, 2007 -

journals.prous.com (CITARE BDI)

Articol citat: Effects of physical and vibroacoustic therapy in chronic pain in juvenile arthritis, LM Ailioaie, C

Ailioaie, C Ancuta… - Revista Romana de …, 2011 - reumatologie.medica.ro

1. Ocena efektów analgetycznych terapii wibroakustycznej w leczeniu dolegliwości bólowych części

lędźwiowo-krzyżowej kręgosłupa u pracowników biurowych., M Drężewska, A Sieroń, Z Śliwiński -

skuteczne-leczenie.pl (CITARE BDI)

Articol citat GOUT-INDUCED BY INFLIXIMAB?-CASE REPORT, …, A Chirana, AE Chiriac, A Codrina - Our

Dermatology Online/ …, 2012 - academia.edu

1.CALCINOSIS CUTIS METASTÁSICA: CALCIFILAXIS (ARTERIOLOPATÍA URÉMICA CALCIFICADA). A

PROPÓSITO DE UN CASO, L Rodríguez, BDM Ortiz, R Contreras… - Our Dermatology …, 2013 -

odermatol.com (CITARE BDI)

2. Giant tophus in the course of gout, with a good response to infliximab, T Pinteala, P Brzezinski - mednet.gr

(CITARE BDI)

Articol citat Importance of posture assessment in ankylosing spondylitis. Preliminary study, MO Roşu, C

Ancuţa, C Iordache… - … medico-chirurgicala a …, 2012 - revmedchir.ro

1. Postural Control and Balance in Ankylosing Spondylitis, T Yildirim, O Yildirim - Medicine Science|

International Medical Journal - ejmanager.com

2. Evidencia científica de la rehabilitación en la espondilitis anquilosante, A Bigorda-Sague, MA Castellano-del-

Castillo… - Rehabilitación, 2014 – Elsevier

Articol citat Aminoacyl-tRNA synthetases in idiopathic inflammatory myopathies: an update on

immunopathogenic significance, clinical and therapeutic implications, CM Ancuta, E Ancuta… - Idiopathic

Inflammatory …, 2011 - cdn.intechopen.com

1. Antisynthetase syndrome: Not just an inflammatory myopathy, S CHATTERJEE, R PRAYSON, C FARVER - Cleveland

Clinic journal of …, 2013 - ccjm.org

Curriculum vitae | Codrina Irena Mihaela ANCUTA

25 | P a g e

Articol citat: Study on the effectiveness of the kinetic method in patients with rheumatic diseases and

temporomandibular joint dysfunction., MD Havriş, C Ancuţa, C Iordache… - … medico-chirurgicala a …, 2012 -

revmedchir.ro

1. ANALYSIS OF THE EFFECTIVENESS OF THE TYPE OF EQUIPMENT OCCLUSIVE PLAN AND SOFT IN RELIEF OF

PAIN IN TEMPOROMANDIBULAR …, A dos Santos Soares, M Medeiros de Oliveira… - International Journal of …,

2013

Articol citat: The Pilates method in ankylosing spondylitis, S Berea, C Ancuţa, S Miu, R Chirieac -

rehabilitation, 2012 - medica.ro

1. Effects of Pilates, McKenzie and Heckscher training on disease activity, spinal motility and pulmonary function in

patients with ankylosing spondylitis: a randomized …, MO Roşu, I Ţopa, R Chirieac, C Ancuta - Rheumatology

international, 2014 - Springer

Articol citat: Effects and safety of rituximab in systemic sclerosis: an analysis from the European

Scleroderma Trial and Research (EUSTAR) group, …, P Airo, JJA Sancho, L Ananjeva, CM Ancuta… -

Annals of the …, 2014 - ard.bmj.com

1. TLR4 knockout ameliorates tissue fibrosis in the murine models of systemic sclerosis, T Takahashi, Y Asano, Y

Ichimura… - Arthritis & …, 2014 - Wiley Online Library

2. Molecular and cellular basis of scleroderma, B Eckes, P Moinzadeh, G Sengle… - Journal of Molecular …, 2014

- Springer

3. Targeting B Lymphocytes in Progressive Fibrosing Mediastinitis, BD Westerly, GB Johnson, F Maldonado… -

American journal of …, 2014 - Am Thoracic Soc

4. B-cell depletion attenuates serological biomarkers of fibrosis and myofibroblast activation in IgG4-related

disease, E Della-Torre, E Feeney, V Deshpande… - Annals of the …, 2014 - ard.bmj.com

5. Анти-В-клеточная терапия при иммуновоспалительных ревматических заболеваниях:

эффективность и переносимость у 229 больных, AП Ананьева, AК Соловьев, AЭ Цанян… - Научно-

практическая …, 2014 - rsp-j.ru

6. Estimating Benefits from Immunesuppressive Treatment in Diffuse Cutaneous Systemic Sclerosis: Data from

the Canadian Scleroderma Research Group, T Choy, M Baron, JE Pope - Open Journal of Rheumatology and

…, 2014 - file.scirp.org

7. Quoi de neuf en Médecine interne?, E Laffitte - Annales de Dermatologie et de Vénéréologie, 2014 - Elsevier

8. Long-term efficacy of B cell depletion therapy on lung and skin involvement in diffuse systemic sclerosis, SL

Bosello, G De Luca, M Rucco, G Berardi… - Seminars in arthritis and …, 2014 - Elsevier

9. Simultaneous downregulation of KLF5 and Fli1 is a key feature underlying systemic sclerosis, S Noda, Y

Asano, S Nishimura, T Taniguchi… - Nature …, 2014 - nature.com

Articol citat: A predictive model for remission and low disease activity in patients with established

rheumatoid arthritis receiving TNF blockers, C Pomirleanu, C Ancuta, S Miu, R Chirieac - Clinical

rheumatology, 2013 - Springer

1. Evaluating drug-free remission with abatacept in early rheumatoid arthritis: results from the phase 3b,

multicentre, randomised, active-controlled AVERT study …, P Emery, GR Burmester, VP Bykerk… - Annals of

the …, 2015 - ard.bmj.com

Articol citat: Lichen planus secondary complications associated with the use of biologic therapy for

rheumatoid arthritis, A Chiriac, L Foia, AE Chiriac, C ANCUŢA… - Romanian journal of …, 2013 - rjme.ro

1.Safety of Anti-Tumor Necrosis Factor Therapies in Arthritis Patients, MG Neuman, RM Nanau - Journal of

Pharmacy & …, 2014 - ejournals.library.ualberta.ca

Articol citat: Work disability remains a major problem in rheumatoid arthritis in the 2000s: data from

32 countries in the QUEST-RA study, T Sokka, H Kautiainen, T Pincus… - Arthritis research & …, 2010 -

arthritis-research.com

1. Systematic literature review on economic implications and pharmacoeconomic issues of rheumatoid

arthritis, G Furneri, LG Mantovani, A Belisari… - Clinical and …, 2012 - clinexprheumatol.org

2. 2011 Consensus of the Brazilian Society of Rheumatology for diagnosis and early assessment of

rheumatoid arthritis, LMH Mota, BA Cruz, CV Brenol, IA Pereira… - Revista brasileira de …, 2011 - SciELO

Brasil

Curriculum vitae | Codrina Irena Mihaela ANCUTA

26 | P a g e

3. The need to address the burden of musculoskeletal conditions, AD Woolf, J Erwin, L March - Best Practice

& Research Clinical …, 2012 – Elsevier

4. Monitoring rheumatoid arthritis, JS Smolen, D Aletaha - Current opinion in rheumatology, 2011 -

journals.lww.com

5. Angiogenesis as a therapeutic target in arthritis in 2011: learning the lessons of the colorectal cancer

experience, N Thairu, S Kiriakidis, P Dawson, E Paleolog - Angiogenesis, 2011 – Springer

6. Economic consequences and potential benefits, B Fautrel, SMM Verstappen, A Boonen - Best Practice &

Research Clinical …, 2011 – Elsevier

7. The incidence of permanent work disability in patients with rheumatoid arthritis in Sweden 1990–2010:

before and after introduction of biologic agents, E Hallert, M Husberg, L Bernfort - Rheumatology, 2012 -

Br Soc Rheumatology

8. Consenso da Sociedade Brasileira de Reumatologia 2011 para o diagnóstico e avaliação inicial da artrite

reumatoide, LM da Mota, BA Cruz, CV Brenol, IA Pereira… - Rev Bras …, 2011 - SciELO Brasil

9. The rationale of pharmacoeconomic analysis in rheumatologic indications, G Turchetti, L Scalone, AO

Della Casa… - Clin Exp …, 2012 - researchgate.net

10. Determinants of work disability in patients with systemic sclerosis: a longitudinal study of the GENISOS

cohort, R Sharif, MD Mayes, PM Nicassio, EB Gonzalez… - Seminars in arthritis and …, 2011 – Elsevier

11. Very early rheumatoid arthritis as a predictor of remission: a multicentre real life prospective study, E

Gremese, F Salaffi, SL Bosello, A Ciapetti… - Annals of the …, 2012 - ard.bmj.com

12. My treatment approach to rheumatoid arthritis, JM Davis III, EL Matteson - Mayo Clinic Proceedings, 2012

– Elsevier

13. Agreement between aggregate and individual-level measures of income and education: a comparison

across three patient groups, CA Marra, LD Lynd, SS Harvard… - BMC health services …, 2011 -

biomedcentral.com

14. Work disability rates in RA. Results from an inception cohort with 24 years follow-up, E Nikiphorou, D

Guh, N Bansback, W Zhang… - …, 2012 - Br Soc Rheumatology

15. Decline in work disability caused by early rheumatoid arthritis: results from a nationwide Finnish

register, 2000–8, VM Rantalaiho, H Kautiainen, S Järvenpää… - Annals of the …, 2012 - ard.bmj.com

16. Methodological issues when measuring paid productivity loss in patients with arthritis using biologic

therapies: an overview of the literature,SMM Verstappen, B Fautrel, S Dadoun… - …, 2012 - Br Soc

Rheumatology

17. Which patients with rheumatoid arthritis are still working?, T Uhlig - Arthritis Research and Therapy,

2010 - biomedcentral.com

18. Prognostic factors for long-term work disability due to musculoskeletal disorders, L Abásolo, C Lajas, L

León, L Carmona… - Rheumatology …, 2012 – Springer

19. Characterization of a novel and spontaneous mouse model of inflammatory arthritis, IA Adipue, JT Wilcox,

C King, CA Rice… - Arthritis Res …, 2011 - biomedcentral.com

20. Negotiating targets with patients: choice of target in relation to occupational state, SM Robinson, DJ

Walker - Rheumatology, 2012 - Br Soc Rheumatology

21. The influence of a< i> TNF</i> gene polymorphism on the severity of rheumatoid arthritis in the

Brazilian Amazon, AL Boechat, NO Boechat, MM Ogusku, MR Alencar… - Cytokine, 2013 – Elsevier

22. About classification of rheumatoid arthritis, DE Karateev, YA Olunin - Rheumatology Science and Practice,

2008 - rsp-j.ru

23. Взаимосвязь клинических характеристик ревматоидного артрита с трудоспособностью и

производительностью труда, ОЮ ВАКУЛЕНКО, ДВ ГОРЯЧЕВ - Научно-практическая …, 2012 -

cyberleninka.ru

24. Impact of modified-release prednisone on functional ability in patients with rheumatoid arthritis, BM

Pfeiffer, S Krenzer, R Dockhorn… - Rheumatology …, 2013 – Springer

25. Management of work disability in rheumatic conditions: a review of non-pharmacological interventions,

MAM Gignac, A Jetha, J Bowring, DE Beaton… - Best Practice & …, 2012 – Elsevier

26. Biological therapy in inflammatory rheumatic diseases: issues in Central and Eastern European countries,

M Péntek, G Poór, P Wiland, M Olejárová… - The European Journal of …, 2014 – Springer

27. Impact of socioeconomic gradients within and between countries on health of patients with rheumatoid

arthritis (RA): Lessons from QUEST RA, P Putrik, T Sokka, S Ramiro, A Boonen - Best Practice & Research

Clinical …, 2012 - Elsevier 28. 类风湿关节炎患者工作能力障碍的现况调查, 张晓盈， 段天娇， 穆荣， 楼放， 李春， 王秀茹… - 中华

风湿病学 …, 2012

Curriculum vitae | Codrina Irena Mihaela ANCUTA

27 | P a g e

29. The role of goal management for successful adaptation to arthritis, RY Arends, C Bode, E Taal… - Patient

education and …, 2013 – Elsevier

30. Burden of disease in treated rheumatoid arthritis patients: Going beyond the joint, M Cutolo, GD Kitas,

PLCM van Riel - Seminars in arthritis and rheumatism, 2014 – Elsevier

31. Predictors of work disability during the first 3 years after diagnosis in a national rheumatoid arthritis

inception cohort, T Olofsson, IF Petersson, JK Eriksson… - Annals of the …, 2014 - ard.bmj.com

32. Costs of rheumatoid arthritis during the period 1990–2010: a register-based cost-of-illness study in

Sweden, A Kalkan, E Hallert, L Bernfort, M Husberg… - …, 2014 - Br Soc Rheumatology

33. Predictors of work disability during the first 3 years after diagnosis in a national rheumatoid arthritis

inception cohort, T Olofsson, IF Petersson, JK Eriksson… - Annals of the …, 2013 - ard.bmj.com

34. Low prevalence of work disability in early inflammatory arthritis (EIA) and early rheumatoid arthritis at

enrollment into a multi-site registry: results from the catch cohort, L Mussen, T Boyd, V Bykerk, F de Leon,

L Li… - Rheumatology …, 2013 – Springer

35. Early rheumatoid arthritis 6 years after diagnosis is still associated with high direct costs and increasing

loss of productivity: the Swedish TIRA project, E Hallert, M Husberg, A Kalkan… - Scandinavian …, 2013 -

informahealthcare.com

36. Sensibility of five at-work productivity measures was endorsed by patients with osteoarthritis or

rheumatoid arthritis, K Tang, DE Beaton, D Lacaille, MAM Gignac… - Journal of clinical …, 2013 – Elsevier;

37. Interaction between smoking and HLA-DRB1* 04 gene is associated with a high cardiovascular risk in

Brazilian Amazon patients with rheumatoid arthritis, N de Oliveira Boechat, MM Ogusku, AL Boechat… -

PloS one, 2012 - dx.plos.org

38. Fit For Work?, K Zheltoukhova, S Bevan, A Reich - … disorders and the …, 2012 - fitforworkeurope.eu

39. Angiogenesis in joint disease: the need for clinical data, EM Paleolog - International Journal of Clinical

Rheumatology, 2010 - Future Medicine

40. Potential of the HAQ score as clinical indicator suggesting comprehensive multidisciplinary assessments:

the Swedish TIRA cohort 8 years after diagnosis of RA, I Thyberg, Ö Dahlström, M Björk, P Arvidsson… -

Clinical …, 2012 – Springer

41. Advances in the treatment of cervical rheumatoid: Less surgery and less morbidity, GW Mallory, SR

Halasz, MJ Clarke - World journal of orthopedics, 2014 - ncbi.nlm.nih.gov

42. Disability mediates the impact of common conditions on perceived health, J Alonso, G Vilagut, ND

Adroher, S Chatterji, Y He… - PloS one, 2013 - dx.plos.org

43. Pacing as a treatment modality in migraine and tension-type headache, A McLean, K Coutts, WJ Becker -

Disability and …, 2012 - informahealthcare.com

44. Situation of rheumatology in Poland in 2012, P Wiland, B Maciazek-Chyra - Reumatologia, 2012 -

termedia.pl

45. Employment in adults with cystic fibrosis, K Targett, S Bourke, E Nash, E Murphy… - Occupational …, 2014

- Soc Occupational Med

46. The International Classification of Functioning, Disability and Health (ICF) Core Sets: Application to a

postmenopausal woman with rheumatoid arthritis and …, AL Lorbergs, NJ MacIntyre - Physiotherapy

theory and …, 2013 - informahealthcare.com

47. Rehabilitation in der Rheumatologie, F Luttosch, C Baerwald - Der Internist, 2010 – Springer

48. The initial treatment strategy and the long-term outcome of early rheumatoid arthritis with special

interest in the FIN-RACo trial and the current Finnish …, V Rantalaiho - 2012 - Tampere University Press

49. Relationship of the clinical characteristics of rheumatoid arthritis to work capacity and efficiency, OY

Vakulenko, OA Krichevskaya, DV Goryachev… - … Science and Practice, 2012 - rsp-j.ru

50. Rheumatology and work, AC Jones, AF Kavanaugh, DJ Walker - Rheumatology, 2010 - Br Soc

Rheumatology

51. Association of employment and working conditions with physical and mental health symptoms for people

with fibromyalgia, C Rakovski, L Zettel-Watson… - Disability and …, 2012 - informahealthcare.com

Curriculum vitae | Codrina Irena Mihaela ANCUTA

28 | P a g e

52. Impact of impaired morning function on quality of life in rheumatoid arthritis: results of an exploratory

patient survey, S Phillips, L Dow - International Journal of Clinical Rheumatology, 2012 - Future Medicine

53. Stan reumatologii w Polsce w 2012 roku, P Wiland, B Maciążek-Chyra - Reumatologia, 2012 - termedia.pl

54. Moving from evidence to practice: Models of care for the prevention and management of musculoskeletal

conditions, R Speerin, H Slater, L Li, K Moore, M Chan… - Best Practice & …, 2014 - Elsevier

55. The Burden of Disease in Rheumatoid Arthritis, T Uhlig, RH Moe, TK Kvien - PharmacoEconomics, 2014 -

Springer

56. Musculoskeletal Disorders and Health Behaviors Among US Workers, AJ Caban-Martinez - 2011 -

scholarlyrepository.miami.edu

57. Angiogenesis in Rheumatoid Arthritis, S Konisti, S Kiriakidis, EM Paleolog - Angiogenesis and

Vascularisation, 2013 - Springer

58. Evaluation eines neuen 7-Gelenke-Ultraschall-Scores zum Therapiemonitoring bei Patienten mit

Rheumatoider Arthritis und Psoriasisarthritis mit …, B Halbauer - 2012 - diss.fu-berlin.de

59. Unity in diversity: Rheumatoid arthritis across countries, S Pandya, P Ghosh - Indian Journal of

Rheumatology, 2014 - indianjrheumatol.com

60. Retentissement professionnel de la sclérodermie systémique, A Bérezné, C Nguyen, L Mouthon - La Presse

Médicale, 2013 - Elsevier

61. Krónikus betegségek biológiai terápiájának alkalmazásával kapcsolatos gazdasági megfontolások [védés

előtt]= Economic consideration of the implementation of …, O Balogh - 2014 - phd.lib.uni-corvinus.hu

(CITARE BDI)

62. Körperliche Aktivität und Sport bei Rheumatoider Arthritis, O Schultz - Aktuelle Rheumatologie, 2012 -

thieme-connect.com

63. Comparison of the long-term outcome for patients with rheumatoid arthritis with persistent moderate

disease activity or disease remission during the first year …, B Combe, I Logeart, MC Belkacemi… - Annals

of the …, 2014 - ard.bmj.com

64. Work ability and work disability evaluation in Saudi patients with rheumatoid arthritis. Special emphasis

on work ability among housewives, N Janoudi, H Almoallim, W Hussein… - Saudi medical …, 2013 -

smj.psmmc.med.sa

65. REVISTA BRASILEIRA DE REUMATOLOGIA, CB de Radiologia - REV BRAS REUMATOL, 2013 - SciELO Brasil

66. Revmatoid artritt i Norge–demografi, sykdomskarakteristika og behandling. En sammenligning med andre

europeiske land og USA, G Haugeberg, EW Rebnord, A Diamantopoulos… - Norsk …, 2012 - ntnu.no

67. Fit For Work?, R Thomas, K Zheltoukhova, S Bevan - fitforworkeurope.eu (CITARE BDI)

68. Name of journal: World Journal of Rheumatology ESPS Manuscript NO: 12240 Columns: REVIEW Oral

creatine supplementation: A potential adjunct therapy …, TJ Wilkinson, TD O'Brien, AB Lemmey -

wjgnet.com

69. О некоторых подходах к количественной оценке снижения производительности труда при

ревматических заболеваниях, ОА Кричевская, ОЮ Вакуленко… - Научно- …, 2012 - cyberleninka.ru

70. Contribution of ethnic group and socioeconomic status to degree of disability in rheumatoid arthritis in

Chilean patients, AM Alarcón, S Muñoz, JS Kaufman, C Martínez… - Rheumatology …, 2014 – Springer

71. Impact of morning stiffness on working behaviour and performance in people with rheumatoid arthritis, K

Mattila, F Buttgereit, R Tuominen - Rheumatology international, 2014 – Springer

72. Availability, Need for, and Use of Work Accommodations and Benefits: Are they related to Employment

Outcomes in People with Arthritis?, MAM Gignac, X Cao, J McAlpine - Arthritis care & research, 2014 -

Wiley Online Library

73. [PDF] Economic evaluation of a tight-control treatment strategy using an imaging device (handscan) for

monitoring joint inflammation in early rheumatoid arthritis, SC Nair, PMJ Welsing, JWG Jacobs… -

DECISION MAKING IN … - dspace.library.uu.nl

74. [PDF] EFFECTS OF ANTI-TNF ALPHA DRUGS ON DISABILITY IN PATIENTS WITH RHEUMATOID

ARTHRITIS: LONG-TERM REAL-LIFE DATA FROM THE LORHEN …, M Filippini, C Bazzani, F Atzeni, PS

Puttini… - downloads.hindawi.com

75. Linguistic Validation into 20 Languages and Content Validity of the Rheumatoid Arthritis-Specific Work

Productivity and Activity Impairment Questionnaire, J Lambert, BB Hansen, B Arnould, G Grataloup… - The

Patient-Patient- …, 2014 - Springer

Curriculum vitae | Codrina Irena Mihaela ANCUTA

29 | P a g e

76. Early rheumatoid arthritis: The performance of the 2010 ACR/EULAR criteria for diagnosing RA, MD

Mjaavatten, VP Bykerk - Best Practice & Research Clinical …, 2013 - Elsevier

77. Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six

Central and Eastern European countries, V Brodszky, P Baji, O Balogh, M Péntek - The European Journal of

Health …, 2014 - Springer

78. Guidelines for the diagnosis of rheumatoid arthritis, LMH Mota, BA Cruz, CV Brenol, IA Pereira… - Revista

brasileira de …, 2013 - SciELO Brasil

79. Stan reumatologii w Polsce w 2012 roku więcej, P Wiland, B Maciążek-Chyra - Reumatologia, 2012 -

ereumatologia.pl

80. A goal management intervention for polyarthritis patients: rationale and design of a randomized

controlled trial, RY Arends, C Bode, E Taal… - BMC musculoskeletal …, 2013 - biomedcentral.com

81. Outcomes of early rheumatoid arthritis–The WHO ICF framework, SMM Verstappen - Best Practice &

Research Clinical Rheumatology, 2013 - Elsevier

82. Determinants Associated with Work Participation in Patients with Established Rheumatoid Arthritis

Taking Tumor Necrosis Factor Inhibitors, SHM Manders, W Kievit… - The Journal of …, 2014 - jrheum.org

83. Work disability and state benefit claims in early rheumatoid arthritis: the ERAN cohort, DF McWilliams, S

Varughese, A Young… - …, 2014 - Br Soc Rheumatology

84. Oral creatine supplementation: A potential adjunct therapy for rheumatoid arthritis patients, TJ Wilkinson,

TD O'Brien, AB Lemmey - World J Rheumatol, 2014 - wjgnet.com

Articol citat Tumor biomarkers in cervical cancer: focus on Ki-67 proliferation factor and E-cadherin

expression, E Ancuţa, C Ancuţa, LG Cozma, C Iordache… - Rom J Morphol …, 2009 - rjme.ro

1. Expression and prognostic value of the Ki-67 in Wilms' tumor: experience with 48 cases, I Jurić, Z

Pogorelić, I Kuzmić-Prusac, M Biočić… - Pediatric surgery …, 2010 – Springer

2. A comparative analysis of clinical and molecular factors with the stage of cervical cancer in a brazilian

cohort SM Amaro-Filho, JE Golub, GJ Nuovo, CB Cunha… - PloS one, 2013 - dx.plos.org

3. SUV on dual-phase FDG PET/CT correlates with the Ki-67 proliferation index in patients with newly

diagnosed non-Hodgkin lymphoma, CC Chang, SF Cho, YW Chen, HP Tu… - Clinical nuclear …, 2012 -

journals.lww.com

4. Lacking hypoxia-mediated downregulation of E-cadherin in cancers of the uterine cervix, A Mayer, M

Höckel, N Schlischewsky… - British journal of …, 2013 - nature.com 5. Survivin, Ki-67 在口腔颌面部非霍奇金淋巴瘤中的表达及竟义, 刘卓星， 刘文玲 - 临床肿瘤学杂志, 2013 -

cqvip.com

6. BANGALORE, KARNATAKA. ANNEXURE II; MG Dijkstra - rguhs.ac.in (CITARE BDI)

7. Existe alteração no mecanismo de adesão celular mediado pela E-caderina nas neoplasias cervicais de

pacientes soropositivas para o HIV?; JB Zimmermmann, H Gobbi, VH MELO - Rev Bras Ginecol Obstet, 2010

- SciELO Brasil

8. Current status of the management of cervical carcinoma stage IB, S DEXEUS, D DEXEUS, MD OJEDA, B

GUIX… - CME, 2010 (CITARE BDI)

9. Molecular Pathology and Diagnostics of Gynecologic Malignancies, RE Shackelford, M Ghayouri, D

Coppola… - Molecular Pathology and …, 2014 - Springer

10. IMMUNOHISTOCHEMICAL ANALYSIS OF UROTHELIAL BLADDER CANCERS, K Bevizova, J Jakubovsky, J

Luha… - OnLine Journal of …, 2013 - thescipub.com

Articol citat: Predictive value of cellular immune response in cervical cancer, E ANCUŢA, C ANCUŢA, F

Zugun-Eloae… - Romanian Journal of …, 2009 - researchgate.net

1. Prognostic impact of lymphocytes in soft tissue sarcomas, SW Sorbye, T Kilvaer, A Valkov, T Donnem, E

Smeland… - PLoS One, 2011 - dx.plos.org

2. Induction of apoptosis with diallyl disulfide in AGS gastric cancer cell line, JE Lee, RA Lee, KH Kim… -

Journal of the Korean …, 2011 - synapse.koreamed.org

3. The effectiveness of postoperative neutrophils to lymphocytes ratio in predicting long-term recurrence

after stomach cancer surgery, YH Kim, WJ Choi - Journal of the Korean Surgical Society, 2012 -

synapse.koreamed.org

4. Proex C para o diagnóstico de lesões intra-epiteliais no colo do útero, AA Pias - 2012 - lume.ufrgs.br

5. Tumor Infiltration by Immune Cells: Pathologic Evaluation and a Clinical Significance, DW Gutkin - The

Tumor Immunoenvironment, 2013 – Springer

Curriculum vitae | Codrina Irena Mihaela ANCUTA

30 | P a g e

6. Prognostic value of adaptive and innate immune system in soft tissue sarcomas, SW Sørbye - 2013 -

munin.uit.no

7. Breast Cancer: CD3+ Tumor Infiltrating Lymphocytes Differences among Molecular Subtypes, NA

Mohammed, SA Ali, SM Saleh, AS Abood - cancer cells - ijser.org

8. Predictive Value of Cellular Immune Response and Tumor Biomarkers in Patients Surgically Treated for

Cervical Cancer in Relation to Clinical Outcomes, E Ancuta, C Ancuta, D Sofroni - cdn.intechopen.com 9. shrew-1 与 MMP-9 蛋白的表达及其联合检测对早期子宫颈鳞癌复发的预测价值, 孙晓彤， 杨毓琴， 李耘

， 王梅， 曲波， 任睿 - 中华妇产科杂志, 2012 - 万方数据资源系统

10. CD3+, CD4+ & CD8+ tumour infiltrating lymphocytes (TILs) are predictors of favourable survival outcome

in infiltrating ductal carcinoma of breast, AS Rathore, S Kumar, R Konwar, A Makker… - The Indian journal

of …, 2014 - ncbi.nlm.nih.gov

11. Manipulation of tumour-infiltrating B cells and tertiary lymphoid structures: a novel anti-cancer treatment

avenue?, K Siliņa, U Rulle, Z Kalniņa, A Linē - Cancer Immunology, Immunotherapy, 2014 – Springer

…. Articol citat: Neoangiogenesis in cervical cancer: focus on CD34 assessment, C ANCUŢA, E Ancuţa, F

Zugun-Eloae… - Romanian Journal of …, 2010 - rjme.ro

1. EFEMP1 expression promotes angiogenesis and accelerates the growth of cervical cancer< i> in vivo</i>, E

Song, Y Hou, S Yu, S Chen, J Huang, T Luo… - Gynecologic …, 2011 – Elsevier

2. Proliferation and maturation of intratumoral blood vessels in non–small cell lung cancer, S Yazdani, Y Miki,

K Tamaki, K Ono, E Iwabuchi, K Abe… - Human pathology, 2013 – Elsevier

3. COX-2 expression and survival in patients with locally advanced cervical cancer treated with

chemoradiotherapy and celecoxib: a quantitative immunohistochemical …, CM Doll, K Winter, DK Gaffney,

JK Ryu… - International Journal …, 2013 - journals.lww.com

4. AD-1, a novel ginsenoside derivative, shows anti-lung cancer activity via activation of p38 MAPK pathway

and generation of reactive oxygen species, LH Zhang, YL Jia, XX Lin, HQ Zhang, XW Dong… - … et Biophysica

Acta (BBA …, 2013 - Elsevier

5. Is there any role of mast cell density and microvessel density in cervical squamous cell carcinoma? A

histologic study with special reference to CD-34 …, SK Mondal, S Dasgupta, PK Mandal… - Indian journal of

…, 2014 - ncbi.nlm.nih.gov

Articol citat: [CITARE] Alendronate for postmenopausal osteoporosis: focus on bone resorption

biomarker, E Ancuta, C Ancuta, C Iordache… - …, 2010 - … LONDON LTD 236 GRAYS INN RD, …

1. Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis

treatment: the secondary prevention of fractures, and primary …, J Burch, S Rice, H Yang, A Neilson, L

Stirk… - Health technology …, 2014 - sefap.org

Articol citat: Changes in bone mineral density during anti-TNF alpha therapy in rheumatoid arthritis

patients, C Ancuta, R Chiriac, E Ancuta… - …, 2007 - SPRINGER LONDON LTD …

1. Gateways to clinical trials, M Bayes, X Rabasseda, JR Prous - Methods and findings in …, 2007 -

journals.prous.com

Articol citat: [Epidemiologic and functional aspects of rheumatoid arthritis in patients attending the

Hospital Rehabilitation Clinic in Iasi, Romania]., AI Costea, C Ancuţa, R Chirieac - … de Medici si

Naturalisti din Iasi, 2010 - europepmc.org

1. Biological therapy in inflammatory rheumatic diseases: issues in Central and Eastern European countries,

M Péntek, G Poór, P Wiland, M Olejárová… - The European Journal of …, 2014 – Springer

05 IAN 2015

CODRINA ANCUTA